



Cite this: *Chem. Soc. Rev.*, 2022, 51, 594

Received 23rd July 2021

DOI: 10.1039/d1cs00100k

[rsc.li/chem-soc-rev](http://rsc.li/chem-soc-rev)

# Biocatalysis making waves in organic chemistry

Ulf Hanefeld, \* Frank Hollmann \* and Caroline E. Paul \*

Biocatalysis has an enormous impact on chemical synthesis. The waves in which biocatalysis has developed, and in doing so changed our perception of what organic chemistry is, were reviewed 20 and 10 years ago. Here we review the consequences of these waves of development. Nowadays, hydrolases are widely used on an industrial scale for the benign synthesis of commodity and bulk chemicals and are fully developed. In addition, further enzyme classes are gaining ever increasing interest. Particularly, enzymes catalysing selective C–C-bond formation reactions and enzymes catalysing selective oxidation and reduction reactions are solving long-standing synthetic challenges in organic chemistry. Combined efforts from molecular biology, systems biology, organic chemistry and chemical engineering will establish a whole new toolbox for chemistry. Recent developments are critically reviewed.

## 1. Introduction

In 1837 Liebig and Wöhler described the action of an enzyme: the crude preparation of hydroxynitrile lyase from the almond *Prunus amygdalus* (PaHNL), which they called emulsin.<sup>1</sup> This emulsin released HCN from a compound also isolated from these almonds, later identified as (*R*)-mandelonitrile. At that time Berzelius had just coined the term catalysis based on, among others, Döbereiner's experiments with platinum.<sup>2</sup> Liebig and Wöhler then went on to disprove that special forces

(*vis vitalis*) were necessary to prepare organic compounds and chemistry was set to continue as a single field of science. But when Fischer published his lock and key hypothesis,<sup>3</sup> chemistry was already split into several fields: in 1907 Buchner received the Nobel prize in Chemistry for his work on cell free application of enzymes for fermentation. But the first enantioselective organic synthesis, the enantioselective addition of HCN to benzaldehyde by Rosenthaler, reverting Liebig and Wöhler degradation of (*R*)-mandelonitrile, was published in 1908 in a biochemistry journal (Scheme 1a).<sup>4</sup> Today this is considered the first wave of biocatalysis.<sup>5</sup> It did not, however, move enzymes centre-stage of Chemistry. This lack of interest in the possibility of enzymes for selective and in particular enantioselective synthesis became

Biocatalysis, Department of Biotechnology, Delft University of Technology, Van der Maasweg 9, The Netherlands. E-mail: [u.hanefeld@tudelft.nl](mailto:u.hanefeld@tudelft.nl), [f.hollmann@tudelft.nl](mailto:f.hollmann@tudelft.nl), [c.e.paul@tudelft.nl](mailto:c.e.paul@tudelft.nl)



Ulf Hanefeld

Ulf Hanefeld received his PhD from the Georg-August-Universität zu Göttingen, having performed the research both with Prof. H. Laatsch (Göttingen) and Prof. H. G. Floss (Seattle). After post-doctoral years with Prof. C. W. Rees (Imperial College London), Prof. J. Staunton (Cambridge) and Prof. J. J. Heijnen and Dr A. J. J. Straathof (TU Delft), he received a fellowship from the Royal Netherlands Academy of Arts and Sciences (KNAW). He

rose through the ranks at the Technische Universiteit Delft and his research in Delft focuses on enzymes, their immobilisation and application in organic synthesis.



Frank Hollmann

Frank Hollmann studied Chemistry at the University of Bonn (Germany). After his PhD with Andreas Schmid (ETHZ Zurich, Switzerland) and a postdoc with Manfred T. Reetz (Max-Planck-Institute for Coal Research, Germany), he worked for some years at Evonik Industries. In 2008 he joined the Biocatalysis Group at the Delft University of Technology where he now is Professor of Biocatalysis.





**Scheme 1** (A) In 1837 Wöhler and Liebig described the PaHNL-catalysed degradation of (*R*)-mandelonitrile. In 1908 Rosenthaler reversed this reaction in the synthesis direction, the first enantioselective reaction described. (B) Since the 1930s the industrial synthesis of L-ephedrine is based on the yeast-catalysed enantioselective synthesis of (*R*)-PAC.

even more visible with the Nobel prize of 1931: the discovery by Warburg of redox enzymes, all of which are highly enantioselective, was the prize for Physiology or Medicine not for Chemistry. Equally the first industrial enantioselective synthesis, the preparation of (*R*)-phenylacetylcarbinol (PAC) for L-ephedrine production catalysed by yeast whole cells dates back to that time and finds little to no recognition in chemistry textbooks (Scheme 1b).<sup>6</sup>

With the recognition of the need for selectivity in general and enantioselectivity in particular also came the recognition of enzymes as promising catalysts. The difference in perspective on selectivity is, however, still visible in the approach that the fields of catalysis take to describing their catalysts: while in most fields a catalyst that is broadly applicable, *i.e.* not very selective, is called versatile, in biocatalysis an enzyme that lacks selectivity is called promiscuous.<sup>7–9</sup> This difference in terminology between the different fields of catalysis can lead to undesirable confusion.<sup>7</sup>

### 1.1 Enzymes: back to chemistry?

Two landmark reviews from 2003<sup>10</sup> and 2012<sup>5</sup> dispelled myths around biocatalysis and identified three waves in biocatalysis. The first wave started with the enantioselective synthesis of (*R*)-mandelonitrile and continued *via* L-ephedrine synthesis towards the formation of selected drugs, such as penicillins all the way to the bulk production of fructose from glucose for the food production. All these processes rely on identifying suitable, naturally occurring enzymes without protein modifications. In all cases use was made of the excellent, if not occasionally too high, selectivity. The vast majority of these developments took place outside main stream chemistry, often in biochemical, food or pharmaceutical laboratories.<sup>11</sup>

#### 1.1.1 Deviating from selectivity → enzyme engineering.

A first step to address the problem of too high selectivity was the application of enzymes evolved for degradation.<sup>7,12,13</sup> The vast majority of hydrolases, be it lipase, esterase, protease or glycolase evolved not for one single substrate as anabolic enzymes did. These enzymes consequently typically have a relaxed substrate scope and might even be not specific for one single functional group but rather show activity towards several groups. This is often seen for lipases, esterases and enzymes that hydrolyse amide bonds. The predominant part of these enzyme have one core structure, the  $\alpha$ , $\beta$  hydrolase fold, and make use of a core catalytic mechanism based on the Asp-His-Ser catalytic triad with variations to address the necessities of the substrate in question.

This was followed by a second and third wave of biocatalysis.<sup>5,10,11,14</sup> In the second wave either well-thought through mutations were introduced or random mutagenesis coupled with massive screening yielded new enzymes that could answer the industrial needs. This included the required selectivity. The third wave combined the two approaches of enzyme improvement, reducing library sizes and allowing rapid screening. As a consequence, the adjustment of the properties of a given enzyme has become almost a standard laboratory technique. Broadening or narrowing the substrate scope,



**Caroline E. Paul**

*Caroline E. Paul obtained her Honours BSc and MSc in Biological Chemistry at the University of Toronto, and her PhD in 2013 in Bioorganic Chemistry at the University of Oviedo with Profs. V. Gotor-Fernández and I. Lavandera. She carried out post-doctoral work with a Marie Curie fellowship with Prof. F. Hollmann at TU Delft followed by a NWO VENI grant at Wageningen University on cofactors biomimetic for oxidoreductases. Since 2018 she is an Assistant Professor in Biocatalysis at TU Delft.*



	B	C	N	O	Si	P	S
H		—	—	—	—	—	—
B		—		—			
C	—	— — — —	— — — —	—	—	—	—
N		— — — —	— — — —	— —		—	— —
O	—	— —	— —		—	—	—
Si		—		—			— —
P		—	—	—		— —	— —
S		— —	— —	—		— —	—
F		—				—	
Cl		—	—				—
Br		—	—				
I		—	—				

**Scheme 2** Synthetic transformations listed on <https://www.organic-chemistry.org/synthesis/>. Green boxes indicate that a biocatalytic equivalent is known; orange indicates that literature reports are available but that the reaction has not yet been applied synthetically. Red indicates a (so far) unknown biocatalytic bond formation.

improving or inverting the regio- or enantioselectivity but also adjusting the optimal reaction conditions of enzymes are state-of-the-art nowadays. Furthermore, the reaction scope of biocatalysis is increasingly extended either by designing new biocatalysts or combinations of enzymes enabling transformations not thought possible a few years ago.<sup>15–18</sup> As a consequence, the scope of biocatalytic bond formations today almost matches the scope of existing chemical technologies (Scheme 2).

The results of this third wave now spreads to all fields of biocatalysis and is the focus of this review.

### 1.1.2 Stability → enzyme engineering and immobilisation?

A perceived disadvantage of enzymes is their stability.<sup>12</sup> Enzymes cannot withstand reaction temperatures significantly above 100 °C. But the question is, do they have to? Chemists are used to applying elevated temperatures to accelerate reactions. The Haber–Bosch process, for example, necessitates reaction temperatures of 400 °C and above to overcome kinetic hurdles in the reduction of the dinitrogen triple bond. At high temperatures, however, the thermodynamic equilibrium of this reaction is unfavourable therefore necessitating high pressures to shift the equilibrium. Biological pendants achieve this at ambient temperatures.<sup>7</sup> Chemists accept that transition metal catalysts are often air and water sensitive. They would not survive a single washing cycling in a washing machine. But modern washing powder contains enzymes that help to clean our clothes under mild conditions, reducing energy consumption (low washing temperatures) and reduce the application of soaps. Enzymes, just like any other catalyst type, bear advantages and disadvantages. It is thus irrational to come up with general statements about a general type of catalysts. Instead, one should

look at them case by case,<sup>7</sup> to allow a judicious choice of the catalyst that suits the desired reaction best.

For example, enzymes involved in primary metabolism under natural conditions (intracellular environment) do not encounter high substrate or product loadings, nor are they typically confronted with drastic changes of conditions. All of this does however, occur in a batch reaction, in particular when working solvent-free.<sup>14,19</sup> Here the second and third wave of biocatalysis help.<sup>5,10,11,14</sup> The engineering of structural aspects helps to improve stability, in particular towards solvents<sup>20</sup> and high concentrations of all reagents, substrates and products.<sup>21,22</sup>

An alternative method of enzyme stabilisation, their immobilisation, has been investigated with similar success and has been reviewed extensively. It is therefore not covered in this overview.<sup>23–29</sup>

**1.1.3 Low substrate loadings → enzyme engineering and alternative solvents?** A second challenge closely linked to stability is the substrate loading. If water is employed concentrations of hydrophobic substrates are often low. Addition of a solvent to improve solubility, two phase systems and neat substrate may all induce stability problems.<sup>14,19</sup> Some enzymes could always be employed under typically chemical conditions, *i.e.* dry solvents, high temperature and very high substrate loads. As already exemplified in the 2003 review<sup>10</sup> and *in extenso* by Klivanov in 2001,<sup>14</sup> they could always be working just like any chemical reagent. The prime example for this ability is *Candida antarctica* lipase B (CALB), but this also applies to many other enzymes.<sup>19,30</sup> The stability problems of the remaining enzymes can be addressed by immobilisation or



in particular the third wave of biocatalysis: enzyme engineering. Directed enzyme engineering has led to a huge extension of the number of stable and versatile enzymes. Here we examine the chemistry that has become possible with this third wave, demonstrating how it has flushed biocatalysis and enzymes right into the centre of chemistry again.

## 2. Chemical transformations catalysed by biocatalysts


Based on the above written the reader might now expect that for the vast majority of chemical conversions a biocatalytic variant is available. This biocatalytic process should then have ideally several advantages over its uncatalysed chemical counterpart. While this status is not yet reached we here demonstrate the many waves that biocatalysis is by now making in organic synthesis. In many cases the biocatalytic methods complement the already available tools, enriching chemistry. We follow the sequence of the waves, C–C bond forming enzymes appeared early (Wöhler, Liebig, Rosenthaler),<sup>1,4,6</sup> subsequently redox enzymes (Warburg) were intensely studied at a later stage.<sup>31,32</sup> We combine this sequence with the disconnection approach common in organic chemistry.<sup>33</sup>

### 2.1 C–C-Bond forming reactions

The formation of C–C bonds is essential for any organic synthesis to establish the carbon framework of the desired compound. This is in particular the case in total synthesis of natural compounds and pharmaceutical chemistry. Here the superior selectivity of enzymes is the basis of many successes. However, this selectivity to date also limits the broad application of enzymes, as there is no single enzyme that catalyses Friedel–Crafts chemistry in general, as  $\text{AlCl}_3$  does.<sup>6,7,15,34,35</sup>

Up to the present time the largest part of the enzyme catalysed C–C bond formations are based on the nucleophilic attack on an aldehyde. This yields 1,2 disconnections in the case of cyanide or the umpolung of a second aldehyde or 1,3 disconnections when an enol(ate) is used as nucleophile.<sup>6,33,35,36</sup> The aldehyde can be replaced by a ketone, though then the reactions often have lower yields as the reaction equilibria are less favourable. Essentially six nucleophiles (in biochemistry called donor) are today broadly utilised in combination with countless aldehydes or ketones (in biochemistry called acceptor) (Scheme 3). Additionally the aldehyde based biocatalytic equivalent of a Pictet–Spengler reaction is already well-known.<sup>37</sup>

**2.1.1 1,2 Disconnection.** This disconnection is part of the first wave of biocatalysis and the possibilities thereof were improved and expanded with each new wave (Scheme 1). The oldest biocatalytic reaction, the attack of cyanide yields chiral 1,2 difunctional cyanohydrins in the case of the HNLs.<sup>4,6,38–41</sup> These enzymes do not require supplementation of the reactions with cofactor. For the second nucleophile, an aldehyde of almost entirely free choice, an umpolung is essential to ensure its attack on the first aldehyde (or ketone). This is enabled by



**Scheme 3** The majority of the today well-established biocatalytic C–C bond formations are based on the attack of a nucleophile on an aldehyde or ketone.

thiamine diphosphate (ThDP), the cofactor required in this disconnection.<sup>35,42,43</sup> Both reactions suffer from an unselective background reaction that can compete with the enzyme catalysed reaction. In the HNL case this can be suppressed by lowering the pH to avoid the chemical, racemic reaction. For the ThDP-dependent enzymes it is the cofactor on its own that is already catalytically active. It should therefore not be utilised in a huge excess but carefully dosed.

**2.1.1.1 HNL-Catalysed reactions.** HNLs catalyse in nature the decomposition of cyanohydrins to release HCN as a defence mechanism.<sup>38,40,41</sup> This catalytic activity is a prime example of convergent evolution. It evolved in many very different organisms, plants and animals utilising very different protein folds and thus catalytic mechanisms. Consequently a wealth of enzymes, both *R*- and *S*-selective is available. These enzymes work with sometimes very different mechanisms, from Lewis metal-catalysed to classical acid base catalysis, and have been further developed by enzyme engineering.<sup>40,41,44,45</sup> Independent of the mechanism, the enzymes are typically utilised in two phase systems at low pH to suppress the undesired background reaction and ensuring high substrate loadings.<sup>38,45</sup> Both industrially and for laboratory purposes the biocatalytic cyanohydrin synthesis is today the standard method.<sup>38,40,41,46</sup> In addition to cyanide, nitromethane can also be employed as nucleophile (donor). This unnatural reaction is possible as both nucleophiles have similar  $\text{p}K_a$  values and size and thus both fit into the active site. The synthesis then is a biocatalytic Henry reaction (Scheme 4).<sup>40,41,47,48</sup>

Recent developments have focussed on even more enzymes from unusual sources such as millipedes<sup>44,51–53</sup> and bacteria,<sup>54–56</sup> the exploration of evolutionary ancestors<sup>57</sup> and other methods to interconvert HNL activity with other enzyme activities, in particular hydrolase activity.<sup>58</sup> Reaction engineering with a special focus of the application of HNLs in flow has recently led to promising results. Single phase organic solvents could be employed and both high space time yields (STY) of up to  $1200 \text{ g L}^{-1} \text{ h}^{-1}$  and cascade reactions were reported.<sup>59,60</sup>








**Scheme 4** (A) Industrially HNLs are employed in biphasic systems. (B) For synthetic purposes they can be employed in organic solvents or biphasic systems. Both *R*- and *S*-cyanohydrins synthesis is straightforward<sup>49,50</sup> and (C) equally the enantioselective Henry reaction can be performed.

**2.1.1.2 ThDP-Dependent umpolungs reactions.** All umpolungs chemistry in nature is based on ThDP as a cofactor. In its unphosphorylated form it is known as vitamin B<sub>1</sub> and chronic lack of it causes the disease beriberi. The protein structure of

the apoenzyme that then together with the ThDP forms the holoenzyme imparts both activity and selectivity to the ThDP.<sup>6,35,42,43</sup> Given its unusual chemistry ThDP will be briefly described here (Scheme 5). Within the holoenzyme the ThDP is



**Scheme 5** (A) Vitamin B<sub>1</sub> in its phosphorylated form as ThDP is folded in the enzyme so that the two aromatic rings are at close to 90° to each other. The amino group can then deprotonate the thiazole ring. (B) The resulting ylide then attacks either an aldehyde or an  $\alpha$ -ketoacid. This results in either case in the carbanion that as donor attacks another carbonyl compound. The new C–C bond is formed and the product released. In all cases the reaction is fully reversible and kinetically controlled.



folded such that the pyrimidine and the thiazolium rings have an angle of 90 degree to each other. The amino group of the aminopyrimidine ring is thus in close proximity of the hydrogen of the C2 of the thiazolium ring and can abstract it. This deprotonation is supported by amino acids from the protein scaffold.<sup>61–63</sup> The resulting ylide can also be viewed as tautomeric carbene.<sup>64</sup> The ylide is then ideally posed to attack a carbonyl compound, the electrophile or acceptor. This acceptor can be either an aldehyde (ketones are very rare due to the steric hindrance) or an  $\alpha$ -ketoacid. In the case of the aldehyde the initially formed adduct undergoes the umpolung; the negative charge now resides on the carbon of the aldehyde carbonyl group. In the case of decarboxylases  $\alpha$ -ketoacids are decarboxylated, again resulting in the umpolung of the carbonyl group. This reactive intermediate can be drawn in two tautomeric forms, the enamine and the carbanion. It attacks the second carbonyl compound, again in most cases an aldehyde as ketones are sterically very demanding. Subsequent to the formation of the new C–C bond the ThDP is again split off and the product is released. The reaction can equally well proceed in reverse. In the case of transketolase this reverse reaction is the natural reaction it catalyses.

For a long time it was assumed that the forward reaction could be made irreversible by utilising  $\alpha$ -ketoacids for the umpolung reaction. The release of gaseous  $\text{CO}_2$  was considered to thermodynamically make the reverse reaction impossible.<sup>65,66</sup> However, recently it has been demonstrated that this is a kinetic effect and that in both cases, with  $\alpha$ -ketoacids and with aldehydes as donor molecule, the reaction is reversible.<sup>67</sup>

All ThDP-dependent enzymes are arrangements of proteins around the ThDP, typically with two ThDP cofactors between

homodimeric proteins.<sup>42,43,61</sup> It is these proteins that determine which molecule reacts with the ThDP, undergoes the umpolung and then acts as donor. This selectivity is typically high and often only relatively small molecules are accepted in the donor pocket. The second pocket enables the docking of the acceptor aldehyde and at the same time determines its orientation. This fixes the stereochemical outcome of the reaction. Elegant analysis of these binding pockets allowed the engineering thereof.<sup>68–72</sup> As a result excellent control of the donor and acceptor molecule as well as the stereoselectivity was gained (Scheme 6). This work was further extended by engineering a decarboxylase in such a way that it could admit formaldehyde as acceptor, making it one of the few enzymes that can convert this toxic compound and at the same time enabling C1 chemistry also for the ThDP-dependent enzymes.<sup>73,74</sup>

Utilising the tools of the second and third wave of biocatalysis, ThDP dependent enzymes were also engineered to accept highly hydrophobic substrates and to enlarge the donor pocket. In this manner not only size but also other properties of the desired donors and acceptors have been taken into account.<sup>67,75–78</sup> Additionally, sequence alignment and screening still yields other ThDP dependent enzymes that further expand the synthetic possibilities.<sup>79</sup>

**2.1.2 1,3-Disconnections – Aldol reactions.** The aldol reaction is the reaction of two aldehydes or ketones with acidic  $\alpha$ -hydrogen that react with each other to a hydroxyl carbonyl or the unsaturated carbonyl (aldol condensation). It requires a large extent of control, (a) which carbonyl compound is the donor, which the acceptor, (b) how to suppress the elimination of water and (c) how to control the stereochemistry of the new



**Scheme 6** Based on the understanding of substrate docking in the active side both the donor pocket and the acceptor pocket can be modulated to accept the desired molecule. In this manner a toolbox of enzymes for all possible combinations could be established.<sup>68</sup>



stereocentre(s). Enzymes solve many of these problems.<sup>6,35,39,73,80,81</sup> As aldolases are commonly employed in water its elimination is readily suppressed. Additionally they are very specific as to which molecule they can activate as donor (Scheme 3). The control of the stereochemistry raises a more general question. When only one stereocentre is established and the potential products are enantiomers the process is purely kinetically controlled and the selectivity of the enzyme determines the outcome of the reaction. When two or more stereocentres are established the outcome can be determined by kinetics if the difference in activation energies is large, or by thermodynamics, if the difference of the activation energies for the different stereoisomers is small.<sup>82</sup> In that case the thermodynamic stability of the stereoisomers determines the final outcome of the reaction. This phenomenon has in particular been observed for glycine dependent aldolases<sup>83,84</sup> but has recently been shown to be a general fact, concerning all aldolases. Indeed, it applies to all catalytic reactions during which two or more stereocentres are generated, independent of whether they are biocatalytic or not.<sup>85</sup>

The aldolases are grouped by the nucleophile they activate into four groups (Scheme 3).<sup>6,35,80</sup> Overall three mechanisms are utilized. The acetaldehyde dependent aldolases utilises the enamine mechanism also known as class I and it is in its essence identical to the enamine chemistry in the organic chemistry textbook. A lysine reacts with the donor and then activates it as enamine which attacks the acceptor aldehyde. For the pyruvate and dihydroxyacetone phosphate (DHAP) dependent aldolases nature evolved two very different mechanisms. In higher plants and animals class I aldolases (enamine mechanism) are found. Class II aldolases are found in fungi and bacteria; here the mechanism is based on the Lewis acid activation of the donor and deprotonation thereof. For the glycine dependent aldolases a cofactor is required, pyridoxal phosphate (PLP). In its reduced, unphosphorylated form it is also known as vitamin B<sub>6</sub>, lack of which causes skin disorders.

**2.1.2.1. Acetaldehyde-dependent aldolases.** The only enzyme known to utilise acetaldehyde as donor is 2-deoxy-D-ribose-5-phosphate aldolase (DERA).<sup>86</sup> It catalyses the reversible aldol reaction yielding 2-deoxyribose-5-phosphate (DR5P) from

acetaldehyde and glyceraldehyde-3-phosphate (G3P). DR5P is stable, as it forms a hemiacetal, shifting the equilibrium to the aldol side. This hemiacetal formation is an element of reaction engineering that is utilised regularly in DERA-catalysed reactions and in aldolase-catalysed reaction in general.<sup>87,88</sup> As the DERA-catalysed reaction is common in nature the number of DERA's is almost unlimited. The application of DERA struggles with one problem. The sensitivity of most DERA's to high acetaldehyde concentrations as acetaldehyde and in particular the side product of acetaldehyde self-condensation, crotonaldehyde, deactivate the enzyme.<sup>86,89</sup> This has been addressed *via* screening and enzyme engineering while at the same time expanding the substrate scope.<sup>89–93</sup> Although this improved the enzyme stability, additional reaction engineering, *i.e.* slow dosing of the acetaldehyde remains necessary. Immobilisation has also given promising results, including applications in flow.<sup>94,95</sup>

DERA is employed industrially.<sup>96–98</sup> For several years already the synthesis of the statin side chain is based on an intriguing double aldol reaction. As the product of the first aldol reaction again yields an aldehyde this new aldehyde can also function as acceptor. After the second aldol reaction the product forms a stable hemiacetal, thus removing the product from the equilibrium. Recently this has been coupled to an ADH-catalysed oxidation yielding the desired lactone (Scheme 7).<sup>99,100</sup> A more elaborate industrial cascade involving DERA is discussed below.

**2.1.2.2. Pyruvate dependent aldolases.** Pyruvate dependent aldolases play a central role in the synthesis of ulosonic acids and sialic acids which has recently been reviewed<sup>35,39,80,81,101,102</sup> and a longstanding industrial example illustrates the power of the approach (Scheme 8), dating back to the first wave of biocatalysis.<sup>103–106</sup> Class II pyruvate dependent aldolases are part of the lignin and polycyclic aromatic compound degrading enzymes. As degrading enzymes they are more flexible for their substrates and therefore in the focus of attention.<sup>107–109</sup> In recent years enzyme engineering allowed to modify the active site of these class II aldolases to extend their scope.<sup>110–112</sup> In particular a number of pyruvate nucleophile analogues was introduced. This not only increases the number of donors but it also means that



**Scheme 7** DERA catalyses a cascade of two aldol reactions. The stable hemiacetal is then oxidised by an ADH to the desired lactone, a key intermediate for the statin side chain.





**Scheme 8** (A) Already for more than 20 years pyruvate dependent aldolases are employed industrially to prepare *N*-acetylneuraminic acid on a ton scale. (B) in recent years the scope of pyruvate dependent aldolases has been extended and they now activate also pyruvate derivatives and establish two stereocentres in one step. The stereoselectivity is, however, often determined by the product stability.

the reaction now establishes two stereocentres. Similar results were obtained with screening efforts and today the pyruvate dependent aldolases accept a range of donors and first steps toward understanding of this relaxed selectivity were made.<sup>113–115</sup> Interestingly also the stereoselectivity of the reaction seems to be somewhat relaxed as is the case with a number of glycine dependent aldolases.<sup>83,84</sup> The earlier already observed thermodynamic stability of the product plays an important role in determining the diastereomeric outcome of the reaction here, too (Scheme 8). While the *E/Z* control over the enolate seems perfect, the attack of the acceptor is prone to lower selectivity.<sup>85,110</sup>

Another special type of pyruvate dependent enzymes have in recent years attracted attention. The hydratase–aldolase produce conjugated systems and therefore catalyse an aldol condensation rather than an aldol reaction. Isolated from organisms that degrade polycyclic compounds, these enzymes catalyse in the synthesis reaction the addition of pyruvate to aromatic aldehydes with subsequent elimination of water. Remarkably these enzymes have also been engineered for the synthesis of quinolones (Scheme 9).<sup>116,117</sup>

**2.1.2.3. DHA(P) dependent aldolases.** The chemistry of the DAHP dependent aldolases is well explored.<sup>6,35,39,80,81</sup> These powerful enzymes establish two stereocentres in a single reaction step. They are versatile catalysts for the synthesis of many sugars and their derivatives<sup>73,80,118–120</sup> and also have been utilised for the preparation of many amino sugars.<sup>121</sup> Overall four stereoisomers can be synthesised with these enzymes. For the *syn*-stereoisomer as well as for one of the *anti*-products the DHAP dependent aldolases are highly stereoselective. However,

for the *anti*-product with the stereochemistry of tagatose, the corresponding tagatose 1,6-diphosphate aldolase (TDP A), displays low diastereoselectivity (Scheme 10). This is possibly due to a thermodynamically controlled product distribution in this case (see also Scheme 8B) as the observed lack of selectivity is diastereoselectivity and not enantioselectivity.<sup>85</sup> While this lack of selectivity is typically considered a disadvantage, it recently has been utilised to prepare rare sugars such as *L*-psicose and *L*-sorbitose.<sup>122</sup>

The DHAP aldolases are a versatile tool for the synthesis of sugars and sugar derivatives but their application is hampered by the low stability and high price of DHAP. To solve this problem two very different approaches were taken. In a classical approach a cascade of enzyme reactions was developed to generate DHAP *in situ*, starting from readily available glycerol. While first cascades required pH shifts this has by now been optimised and can even be applied in flow.<sup>80,120,123,124</sup> The enzymatic DHAP generation has also been demonstrated to work well with any of the DHAP dependent aldolases. However elegant these approaches might be, the best answer to the problem is the direct application of dihydroxyacetone (DHA) instead of DHAP.


Genetic modification of *L*-rhamnulose-1-phosphate aldolase (Rha 1-PA) in the initial high throughput approach were outside the DHAP binding pocket.<sup>125</sup> A second, more focussed approach, lead to modification of the DHAP binding pocket, making it more suitable for DHA.<sup>126,127</sup> An even greater step forward was the results of a screening effort. Fructose-6-phosphate aldolase (FSA) does not require DHAP but DHA.<sup>128,129</sup> This enzyme has completely replaced FDP A. Today



**Scheme 9** (A) Hydratase–aldolases are pyruvate dependent and degrade polycyclic compound. (B) Engineering of a hydratase–aldolase enabled the synthesis of quinolones. The unstable amino group of the benzaldehydes was released just before the enzyme-catalysed reaction.







**Scheme 10** DHAP dependent aldolases establish two stereocentres in a single step. These enantioselective aldolases add to and complement chemical aldol technology. Formation of *syn*-products is catalysed with excellent enantio- and diastereoselectivity by rhamnose 1-phosphate aldolase (Rha 1-PA) and fructose 1,6-diphosphate aldolase (FDP A). *anti*-Products are formed with excellent enantio- and diastereoselectivity catalysed by L-fucose 1-phosphate aldolase (Fuc 1-PA), while tagatose 1,6-diphosphate (TDP A) aldolases displays lower diastereoselectivity.



**Scheme 11** (A) Wild type D-fructose-6-phosphate aldolase (wt-FSA) does not require a phosphorylated DHAP but accepts DHA instead. (B) Mutations expanded the scope on the side of the donor molecule significantly, including even cyclic ketones. (C) The acceptor aldehyde can be varied extensively. Chloroperoxidase (CPO) catalysed *in situ* generation of sensitive aldehydes that then are converted into a precursor of D-fagomine.<sup>136</sup>

modified Rha 1PA and FSA are utilised for countless syntheses of sugar derivatives and aliphatic alkaloids (Scheme 11).<sup>73,80,120,121</sup> The donor in these enzyme variants is not limited to DHA, also other aliphatic and even cyclic ketones can be employed. The acceptor displays an even wider substrate range, including aromatic aldehydes.<sup>130–135</sup>

**2.1.2.4. Glycine dependent aldolases.** The glycine dependent aldolases require PLP as cofactor.<sup>6,35,39,80,137–139</sup> This is essential for the activation of the donor. The amino group of the glycine is covalently bound to the cofactor and then attacks the acceptor. These enzymes convert a broad range of acceptors, inducing aromatic aldehydes and formaldehyde.<sup>73</sup> Again the number of donors is very limited, next to glycine a small number of other amino acids with sterically not very demanding side chains can be utilised. The best studied enzymes are the threonine aldolases

(TA). It was demonstrated that both the D- and the LTA are often hampered by low diastereoselectivity.<sup>83,84</sup> While stereocontrol over the  $\alpha$ -C is excellent the  $\beta$ -stereocentre is often badly defined. As explained above the more stable *threo*- or *syn*-products are the products under thermodynamic control, even if the enzyme has *trans*-selectivity. This problem has been approached by reaction engineering, *i.e.* utilising kinetic control, or by protein engineering.<sup>137,138,140</sup> The equally glycine dependent aldolase serine hydroxymethyltransferase (SHMT) often complement the TA and together these enzymes enable new approaches to amino sugars, amino acids and pharmaceutically relevant 1,2 amino alcohols. In particular combinations with other aldolases allow for highly stereoselective syntheses (Scheme 12).<sup>141–143</sup>

**2.1.2.5. Pictet–Spenglerases.** This group of enzymes is part of the many enzymes that are involved in alkaloid biosynthesis





**Scheme 12** (A) Threonine aldolases catalyse the formation of a wide range of amino alcohols. (B) Glycine dependent aldolases in combination with other aldolases enable the synthesis of many alkaloids.

which have been extensively reviewed. The chemistry is based on imine formation and subsequent Mannich chemistry in the case of the aliphatic substrates and Pictet–Spengler cyclisation in the case of aromatic substrates.<sup>37,144–146</sup> The aliphatic substrates are often synthesised with aldolases (see above). For the aromatic alkaloids here phenethylamine or its derivatives react with the suitable aldehyde, forming the imine. The Pictet–Spenglerase then catalyses the cyclisation leading to tetrahydroisoquinolines. The best studied enzyme is the norcoclaurine synthase (NCS). It has been carefully evolved to accept many different substrates and was recently utilised for the formation spiro tetrahydroisoquinoline alkaloids (Scheme 13).<sup>147,148</sup>

**2.1.3 Methyltransferases.** Chemically the introduction of a methyl group is plagued by two problems, the low chemo-selectivity that leads to unspecific methylation of hydroxyl-, amino- and other functional groups in addition to the desired

C–C bond formation. The second problem is the difficulty to introduce such a small group stereoselectively. For both problems a limited number of enzymes is available. The selective alkylation of aromatic compounds is restricted to electron rich compounds,<sup>149–152</sup> and for the enantioselective alkylation of aliphatic compounds much is known from biosynthetic research but has not been implemented.<sup>153</sup> All these enzymes display excellent chemo selectivity, as do the enzymes specialised in O-, N- and S-alkylation. Significantly more steps have been made by extending the range of alkyl groups transferred far beyond the methyl-group (Scheme 14) and different recycling systems for the expensive cofactor SAM have recently been reviewed.<sup>154,155</sup>

**2.1.4 Acyltransferases.** The Friedel–Crafts acylation is a standard reaction in organic chemistry, albeit that the classical variant with AlCl<sub>3</sub> generates large amounts of waste. This has



**Scheme 13** (A) Engineered NCS enables the enantioselective Pictet–Spengler cyclisation of chiral dopamine derivatives. (B) Equally spiro compounds are accessible *via* engineered NCS, catalysing in this case ring closure starting from a ketone rather than an aldehyde.





**Scheme 14** Methyl transferases chemoselectively alkylate electron rich aromatic compounds and enantioselectively ketoacids. While very selective for C–C bond formations, they accept a range of other alkyl groups in addition to the methyl group.



**Scheme 15** (A) ATase catalyzes the disproportionation of a singly acylated phenol. (B) Engineered ATase can introduce a range of different acyl groups, starting with activated acyl donors in excess.

been addressed with zeolite catalysis but not all substitution patterns are accessible. Intriguingly enzymes offer a new approach. A C-acyltransferase (ATase), an enzyme that transfers an acyl group while forming an C–C bond, enables chemistry complementary to the chemical approaches.<sup>156–158</sup> The natural reaction is a disproportionation (Scheme 15A) which means that a large excess of acylating reagents needs to be employed for high conversions. To date only reactive phenols can be converted. Rational engineering has expanded the range of compounds converted.<sup>159,160</sup> As acylating reagents reactive enol-esters, thioesters or phenylester can be employed and a variety of different acyl groups can be introduced (Scheme 15B).

**2.1.4 Carbene-type C–C-bond formations.** Heme enzymes are able to mediate carbene-type C–C-bond formations. Around 2013, the group of Frances Arnold (Nobel prize in Chemistry in 2018) started investigating the potential of the so-called P411-mutants of the well-known P450 monooxygenases (wherein the distal cysteine ligand has been exchanged to a serine).<sup>161,162</sup> This substitution opened up an entirely new and unexpected world of C–H-functionalisation chemistries that until then had not been sought for. Ever since then the Arnold group has been

developing new catalysts for the functionalisation of C–H-bonds (Scheme 16).<sup>163</sup>

## 2.2 Selective functionalisation of C–H bonds (C–H to C–X)

Selective functionalisation, especially oxyfunctionalisation of non-activated C–H bonds is a showpiece of biocatalysis. Chemical catalysts exhibiting sufficient oxidation power to activate C–H bonds are recurrently plagued by selectivity issues whereas oxidoreductases often exhibit excellent regio- and stereoselectivity.

The synthetic breadth of enzymatic oxyfunctionalisation chemistry has been covered by various review articles.<sup>31,171–176</sup>

**2.2.1 Hydroxylation reactions.** Mostly monooxygenases and peroxygenases are in focus as catalysts for the selective hydroxylation of aromatic and aliphatic C–H bonds.

**2.2.1.1. Aromatic hydroxylation reactions.** A range of flavo-protein monooxygenases (FPMOs) are available for the selective *ortho*- or *para*-hydroxylation of activated arenes such as phenols (Scheme 17).

Though, in principle a broad range of enzymes is available,<sup>171</sup> only few transformations have found preparative





Scheme 16 Direct C–H activation using P411 enzymes forming Fe carbene species.<sup>161,162,164–170</sup>

applications such as the *ortho*-hydroxylation of *ortho*'-substituted phenols catalysed by the 2-hydroxy biphenyl-3-monooxygenase from *Pseudomonas azelaica* (HbpA).<sup>177,178</sup> The wild-type enzyme shows high preference for 2-hydroxy biphenyl, which can be relaxed by enzyme engineering.<sup>179–181</sup>

Less activated arenes such as benzene are not converted by the above-mentioned biocatalysts but by some higher redox-potential heme- and non-heme iron monooxygenases.<sup>176</sup> The catalytic mechanism of these hydroxylation reactions differs somewhat from the mechanism of FPMOs involving an intermediate arene epoxide, which spontaneously rearranges into the final phenol product (Scheme 18).

P450 monooxygenases such as the enzyme from *Bacillus megaterium* (P450BM3) have been studied extensively for the ring-hydroxylation of benzene and its derivatives.<sup>182–187</sup> Especially in case of alkyl substituted arenes the regioselectivity can be rather poor, yielding complex mixtures of ring- and side-chain hydroxylated products. Enzyme engineering however can alleviate this issue.<sup>185</sup>

An interesting enzymatic cascade utilising an engineered P450BM3 in combination with arbutin synthase was reported recently by Reetz and co-workers (Scheme 19).<sup>184</sup> The semi-rationally designed P450BM3 variant enabled selective

*para*-dihydroxylation of benzene (devoid of over-oxidation products commonly observed in chemical processes). Coexpression with arbutin synthase yielded an *E. coli* catalyst transforming benzene into arbutin with 60% isolated yield.

Next to the monooxygenases, also peroxxygenases are worth mentioning as catalysts for the hydroxylation of arenes.<sup>188–191</sup> Issues associated with the peroxidase activity of peroxxygenases resulting in undesired radical polymerisation of the phenol products can be circumvented by the addition of antioxidants or using engineered peroxxygenases.<sup>192,193</sup>

Next to the above-mentioned oxygenases, also a range of dehydrogenases are known (and used industrially) for the *ortho*-hydroxylation of pyridines (Scheme 20).<sup>194–196</sup> The O-atom introduced does not stem from molecular oxygen (as to be expected from a monooxygenase-catalysed hydroxylation) but from water.<sup>197</sup> The mechanism of this reaction is yet to be elucidated.

Finally, also aromatic nitration is worth being mentioned here. Even though this activity is rarely found in nature,<sup>198</sup> the P450 monooxygenase from *Streptomyces scabies* (P450 TxtE) catalyses the nitration of tryptophan.<sup>199–202</sup> In a directed evolution approach, Arnold and co-workers were even able to modulate the regioselectivity of the nitration reaction (Scheme 21).<sup>200</sup>






## A Simplified overall mechanism of flavo-enzyme catalysed oxyfunctionalisation reactions



## B Key-steps in the hydroxylation of activated arenes



**Scheme 17** Aromatic hydroxylation of activated arenes (e.g. phenols) by FPMOs. (A) the general catalytic cycle of FPMOs comprises NAD(P)H-dependent reduction of the enzyme-bound flavin prosthetic group followed by (multistep, the individual intermediates are not shown) activation of  $O_2$  as flavin-4a-hydroperoxoflavin, which performs the oxyfunctionalisation reaction; the catalytic cycle is closed after water elimination. (B) The reactive 4a-hydroperoxoflavin is capable of electrophilic attack at electron-rich arenes such as phenols.

Though the catalytic activity of the enzyme still needs improvement, this method bears considerable synthetic potential.

**2.2.1.2. Aromaticity breaking oxidation reactions.** The majority of biocatalytic transformations of aromatic compounds yield aromatic products. Comparably few aromaticity-breaking transformations are known so far. The most prominent example for this is the *cis*-dihydroxylation of arenes using dioxygenases (Scheme 22). Particularly Hudlicky and co-workers have extensively explored the synthetic possibilities that dioxygenases offer for the organic chemist<sup>203–205</sup> A range of (recombinant) dioxygenases are nowadays available for the regio- and stereoselective *cis*-hydroxylation of a broad range of arenes. As chemical alternatives exhibiting comparable selectivity patterns are rare, these catalysts have been recognised early on by preparative organic chemists in natural product synthesis (Scheme 22).

Aromatic hydroxylation reactions using heme-dependent enzymes proceed *via* an unstable arene oxide intermediate, which spontaneously rearranges into the corresponding phenol product (Scheme 18).<sup>191,212</sup> This intermediate, however, can also be trapped *via* nucleophilic attack yielding *trans*-disubstituted cyclohexadienes (Scheme 23).<sup>213</sup>

Very recently, some new flavin-dependent monooxygenases have been discovered that catalyse the aromaticity-breaking

hydroxylation of resorcinol derivatives.<sup>214</sup> So far the enzymes TropB, SorbC and AzaH with complementary site- and stereo-selectivities have been identified from biosynthetic pathways. Like other flavin-dependent monooxygenases, these enzymes utilise 4a-hydroperoxoflavin as oxidation agent and direct it to the *ortho*- or *para*-position of a pre-existing OH substituent. Their selectivity, however, prefers attack at substituted ring-C-atoms. The resulting  $\sigma$ -complex therefore cannot collapse *via* simple deprotonation and re-aromatisation but rather by *ortho*-quinol formation (Scheme 24).

So far, few preparative examples using this promising reaction have been reported but we are confident that further mechanistic understanding and broadening of the substrate scope will result in a range of useful catalysts/transformations for the organic chemist.


**2.2.1.3 Hydroxylation of  $sp^3$  C–H bonds.** The inertia of  $sp^3$ -hybridised C–H bonds (even in ‘activated’ benzylic or allylic position) requires highly potent O-transfer agents, which are rarely selective. P450 monooxygenases combine both properties by placing the highly active oxyferryl ( $Fe^{IV}=O^+$ ) species (*in situ* generated from its resting  $Fe^{III}$  state) in the well-defined framework of the enzyme active site. The same also controls binding of the substrate and thereby its positioning towards the



## A Simplified catalytic mechanism of P450 monooxygenases (and peroxygenases)



## B The hydroxylation of arenes proceeds via an intermediate arene epoxide



**Scheme 18** Simplified mechanism of P450 monooxygenase-catalysed activation of molecular oxygen resulting in the oxygenating species 'compound I' (formally an Fe(v) oxo species (a)). The reductive activation of molecular oxygen comprises sequential single electron reduction of the enzyme-bound iron and water elimination of the Fe-bound  $O_2$ -species. In the presence of (already reduced)  $H_2O_2$ , compound I can also be formed directly from the resting Fe(III) state via the hydrogen peroxide shunt pathway. B: Aromatic compounds are converted into the corresponding phenols by a sequence of compound I-mediated epoxidation of the aromatic ring followed by spontaneous re-arrangement into the final product (NIH shift).



**Scheme 19** Arbutin synthesis using an engineered P450BM3 variant to transform benzene into catechol.

oxidising agent. This way, though various positions within the starting material could react, only few of them get close enough to the oxoferryl species to react. Fatty acids for example can be hydroxylated selectively in  $\alpha$ -,<sup>215</sup>  $\beta$ -,<sup>216</sup> or  $\omega$ -position,<sup>217–220</sup> depending on the enzyme used. More recently, 'in-chain'

hydroxylating P450 monooxygenases have also been reported,<sup>221,222</sup> giving rise to the assumption that soon a set of P450 monooxygenases with tailored selectivity to selectively transform a given C-H-bond within an alkyl chain will be available.






**Scheme 20** Industrial examples of *ortho*-hydroxylating transformations of pyridine derivatives.<sup>194</sup> The carboxylate groups shown in blue were obtained from the biotransformation of the corresponding nitrile.

The potentially enormous versatility of (non)-heme mono-oxygenases for the selective oxyfunctionalisation often is challenged by either too high or too low selectivity. As a rule of thumb, monooxygenases involved in specific biosynthetic pathways such as secondary metabolites tend to be highly substrate specific. Already small modifications within the structure of the starting material compared to the natural substrate can lead to complete inactivity of a given enzyme. Enzymes playing a role in detoxification/degradation tend to be rather unselective, converting a broad range of starting materials albeit with often low selectivity.

Enzyme engineering has proven being a powerful tool to address those selectivity issues (Scheme 25).

### 2.2.2 Heteroatom functionalisation of C–H bonds

**2.2.2.1 Amination of C–H bonds.** So far, no natural enzyme is known to catalyse the direct amination of C–H-bonds. Nevertheless, this reaction can be realised in a cascade




**Scheme 21** Regioselective nitration of tryptophan with the P450 monooxygenase from *Streptomyces scabies* (P450 TxtE) and one of its mutants.



**Scheme 22** Selection (incomplete) of natural products synthesised from dioxygenase products:<sup>206</sup> indigo,<sup>207</sup> pinitol,<sup>208</sup> prostaglandins,<sup>209</sup> cladospolide,<sup>210</sup> or nangistine.<sup>211</sup>





**Scheme 23** Peroxygenase-catalysed epoxidation of aromatic compounds followed by either a spontaneous rearrangement reaction (NIH shift) yielding phenols or by reacting the intermediate with nucleophiles yielding *trans*-disubstituted cyclohexadienes.


approach comprising C–H-bond hydroxylation followed by oxidation of the resulting alcohol and reductive amination of the carbonyl intermediate as exemplified by Turner and co-workers.<sup>228,229</sup>

The previously mentioned P450 monooxygenases also here opened up new possibilities.<sup>161,162</sup> The functionalisation of C–H-bonds enabled the direct amination starting again with the appropriate reactive nitrogen species (Scheme 26).

**2.2.2.2 Halogenation of C–H-bonds.** In recent years, biocatalytic methods introducing halide atoms into (non)activated



**Scheme 24** Aromaticity-breaking hydroxylation of substituted phenols.



**Scheme 25** Selected examples of regio- and enantioselective hydroxylation of diverse hydrocarbons by means of (engineered) P450 monooxygenases. (a) regioselective hydroxylation of fatty acids in  $\alpha$ -,<sup>215</sup>  $\beta$ -,<sup>216</sup>  $\omega$ -7,<sup>221,222</sup>  $\omega$ - and  $\omega$ -1-position;<sup>217–220</sup> (b) hydroxylation of 11-deoxycortisol;<sup>223,224</sup> (c) P450BM3 mutants for selective hydroxylation of cyperenoic acid;<sup>225</sup> (d) P450 BM3 mutants for the selective hydroxylation of artemisinin;<sup>226</sup> or (e) hydroxylation of 1,4- and 1,8-cineole.<sup>227</sup>








Scheme 26 Direct C–H activation using P411 enzymes forming Fe<sup>IV</sup> nitrene species.<sup>230,231</sup>

C–H bonds have been receiving an increasing interest from the academic community.<sup>232,233</sup> Today, a range of highly selective halogenases (halogenating monooxygenases) and haloperoxidases are available. Scheme 27 gives a representative overview over the biocatalytic halogenation reactions available today.


From a synthetic perspective, halogenases and haloperoxidases can be distinguished. Halogenases excel by their often

superb regio- and stereoselectivity as exemplified in Scheme 27. For example, for the halogenation of substituted aromatics, *o*-, *m*- and *p*-selective enzymes are available either from natural or from man-made diversity;<sup>232–238</sup> impressively demonstrating how chemical properties of the starting materials (such as the *o*- and *p*-directing influence of electron donating substituents) can be over ridden by enzyme selectivity. In addition to the


#### a) flavin-dependent halogenases



#### b) Fe-dependent halogenases



#### c) haloperoxidases



Scheme 27 Selection of enzymatic halogenation reactions.



flavin-dependent halogenases, Fe-dependent halogenases are also increasingly moving into the focus of the research community.<sup>232,234</sup> These enzymes exhibit an even stronger halogenating capacity and are capable of selective halogenation of even non-activated  $\text{sp}^3\text{-C-H}$ -bonds.

This enormous potential, however, is impaired by the comparably low activity. In case of the flavin-dependent halogenases, catalytic activities in the range of several turnovers per minute are the rule rather than the exception.<sup>239</sup> To some extent this can be explained by the molecular architecture of these enzymes comprising an NAD(P)H:flavin oxidoreductase and a halogenase subunit, functionally connected *via* the diffusible reduced flavin ( $\text{FADH}_2$ ).<sup>240,241</sup> This makes flavin-dependent halogenases particularly susceptible to spontaneous oxidative uncoupling. On the other hand, this also enables simplifying the complex electron supply chain by other chemical reductants.<sup>240,242,243</sup> Despite the rather low activity, Sewald and co-workers have established the gram-scale halogenation of tryptophan<sup>235</sup> also an indigo precursor<sup>244</sup> or as starting material for Pd-catalysed cross coupling reactions.<sup>245,246</sup>

In contrast, haloperoxidases excel by their superb catalytic activity reaching hundreds of turnovers per second even upon prolonged reaction times. Haloperoxidases, however, catalyse the  $\text{H}_2\text{O}_2$ -driven oxidation of halides ( $\text{Cl}^-$ ,  $\text{Br}^-$  and  $\text{I}^-$ ) into the corresponding hypohalites,<sup>247–249</sup> which then react spontaneously (non-enzymatically) with the starting material. As a consequence, the selectivity of haloperoxidase-catalysed halogenation reactions of activated aromatics such as phenols,<sup>247,250</sup> or pyrroles,<sup>251–253</sup> is dictated by the chemical reactivity of the starting material. Nevertheless, haloperoxidases have been demonstrated to be useful catalysts to initiate hypohalite-initiated reactions such as (aza)-Achmatowicz reactions,<sup>254–256</sup> halolactonisation reactions,<sup>257–259</sup> or oxidative decarboxylation of amino acids.<sup>260–262</sup>

**2.2.4 Baeyer–Villiger oxidations.** The so-called Baeyer–Villiger monooxygenases (BVMOs) deserve being mentioned here. These flavin-dependent enzymes can be engineered to either favour formation of the ‘normal’ or ‘abnormal’ ester (or lactone) by controlling the migration tendency of the carbonyl substituents.<sup>263–265</sup> Therefore, these enzymes have traditionally been in focus for the synthesis of chiral esters and lactones

e.g. as flavour and fragrance compounds.<sup>266</sup> More recently, they are moving into the focus for the synthesis of lactone building blocks for polyester synthesis.<sup>267–270</sup>

**2.2.5 Miscellaneous.** In addition to the above-mentioned, C–H functionalisation reactions, further P450 mutants have been discovered to catalyse the formation of C–S,<sup>271</sup> C–B<sup>272</sup> C–Si,<sup>273,274</sup> Si–O<sup>275</sup> and S–N-bonds.<sup>276</sup>

## 2.3 Functional group interconversions

The interconversion of functional groups is at the heart of the disconnection approach and retrosynthesis. It allows to utilise synthons that are at first glance very different from the desired product. Nature struggles with similar synthetic problems as chemists do in the laboratory (this should in particular be true in natural product synthesis) and thus a multitude of enzymes is available that catalyses selective interconversions.

**2.3.1 Reactions around the carboxylate group.** The most applied class of enzymes are the hydrolases. Almost 50% of all enzyme applications concern hydrolysis or synthesis of esters or amides, but also nitriles. As the majority of the enzyme catalysed reactions are performed in water, hydrolase catalysed reactions are a straightforward starting point, with the obvious advantage that the solvent is a reagent. Since it is always in huge excess the equilibrium of the reaction automatically is on the hydrolysis side. This chemistry is today fully developed; as is the application of hydrolases in dry solvent to revert the equilibrium to prepare esters or amides. Even for nitriles viable routes have been developed, as highlighted below (Scheme 28). Indeed, this chemistry is today textbook chemistry<sup>7,8</sup> and is therefore not covered in this review.

Three recent developments will however be highlighted that added greatly to scope of the chemistry: ester and amide synthesis is water, PET hydrolysis and nitrile formation.

**2.3.1.1. Synthesis of esters and amides in water.** A major breakthrough in the application of hydrolases is the introduction of the acyltransferases and similar enzymes.<sup>277</sup> These enzymes are closely related to lipases and esterases,<sup>278</sup> however, they catalyse the transfer of an acyl group under aqueous conditions.<sup>279,280</sup> This phenomenon had already been observed for a number of lipases such as CALA and CpLip2 but the scope



**Scheme 28** Enzyme catalysed functional group interconversion and protection group chemistry of nitriles, esters, amides and acids. All of the enzymes can be enantioselective and the reactions can be utilised for kinetic resolutions.





**Scheme 29** MsAcT catalyses the transesterification of primary alcohols with ethyl acetate in water as solvent. It also displays perhydrolase activity, generating peracid from esters. They can subsequently enable Baeyer–Villiger reactions. The BV reaction is not enzyme catalysed.

was still rather limited.<sup>280,281</sup> Strictly speaking this is a transesterification but since straightforward starting molecules as ethyl acetate or vinyl acetate are used in combination with alcohols of choice, it is viewed as ester synthesis.<sup>7,8</sup> In particular the acyltransferase from *Mycobacterium smegmatis* (MsAcT) led to a burst of new applications.<sup>282</sup> This octameric enzyme, structurally closely related to  $\alpha,\beta$ -hydrolases like the esterases, was first described in 2007 to show unusual transesterification activity that allowed the preparation of esters, starting from ethyl acetate and an alcohol. It was demonstrated that the reaction was independent of whether ethyl acetate or water was the solvent. Additionally MsAcT displayed perhydrolase activity, *i.e.* the property to convert esters like ethyl acetate in the presence of hydrogen peroxide into their peracids (Scheme 29).

Initially it was the latter activity that was utilised. MsAcT was immobilised and included in paint.<sup>283</sup> This paint displayed a strongly disinfecting property and could be applied in rooms that require high hygiene standards. Furthermore, it was demonstrated that the peracids generated in the presence of 60% aqueous peroxide could be used in Baeyer–Villiger-oxidations.<sup>284</sup> However, as the enzyme is not catalysing the oxidation reaction, no stereoselectivity was observed (Scheme 29).

The key breakthrough was the controlled synthesis of esters in water. After a preliminary study which indicated both activity

and enantioselectivity, it was shown that MsAcT can be used in water to perform a successful transesterification. MsAcT displays a very high preference of the formation of esters from activated acids and alcohols, in particular primary ones (Scheme 30). In contrast, lipases and esterases hydrolyse the activated acid straightaway. This special property of MsAcT opens up new possibilities. Remarkably not just ethyl acetate can be utilised as activated acid but a range of vinyl esters can be used, too. This underlines the high selectivity of MsAcT for ester synthesis rather than hydrolysis.<sup>285–287</sup>

Careful investigation of the reaction revealed an underlying principle that was already known from the industrial synthesis of penicillins but was to date perceived to be limited to amide synthesis (Scheme 30). Both, in the penicillin acylase catalysed penicillin synthesis and the MsAcT-catalysed ester formation an activated acid will react with a nucleophile more rapidly than with water. This leads to product formation, in the case of penicillin acylase the amide bond, in the case of MsAcT an ester. Hydrolysis of the activated acid and the product is significantly slower than product formation but good control of the reaction kinetics is essential. Otherwise full hydrolysis will still occur.<sup>82,280,288</sup> Soon it was demonstrated that MsAcT can also be employed to synthesise amides in water, broadening its applicability.<sup>289,290</sup> In the latter case it follows the kinetic model described earlier for the penicillin synthesis.



**Scheme 30** (A) Synthesis of esters in water catalysed by MsAcT. Either ethyl acetate or more reactive acid derivatives such as vinyl acetate can be utilised. (B) The formation of an amide in water is based on the rapid conversion of an activated acid, here an ester, with an amine to an amide. The competing hydrolysis of the starting material and of the product are relatively slow and thus high yields of amide can be achieved. (C) MsAcT can utilise esters as activated acids and catalyses their transesterification to the desired product. Again the competing hydrolysis of the starting material or the desired product is slow and thus high yields of ester can be obtained even though the solvent is water.



MsAcT displayed good activity in the ester synthesis, both in batch and in flow chemistry.<sup>285,291–293</sup> Engineering extended the substrate scope and improved as well as inverted the enantioselectivity. Today a wide range of primary and secondary alcohols can be esterified, the latter enantioselectively both to *R* or *S* ester.<sup>285–287</sup> As with other hydrolases, tertiary alcohols and their esters remain a bottleneck. The search for homologous enzymes with similar characteristics has expanded the range of enzymes available for this type of chemistry. Carboxylesterases of family VIII as well as an alcohol acyl transferase from yeast show great promise.<sup>294–296</sup> A particularly noteworthy approach is the application of CAR for the synthesis of esters in water.<sup>297</sup> While up to now limited to primary alcohols, it shows that the catalytic machinery or several enzymes might be suitable for ester synthesis in water.

The results described so far are not limited to batch. It was shown that MsAcT also works well for the synthesis of esters and amides in water or in biphasic mixture of water and acyl donor in flow, and this chemistry was broadly explored (Scheme 31).<sup>298–300</sup>

A single mutation of the nucleophile in the catalytic triad of MsAcT revealed even more possibilities for the application of this intriguing enzyme. By changing the catalytic triad from the standard Ser-His-Asp to Cys-His-Asp the hydroxy group of serine was replaced by the thiol of cysteine. This enabled the synthesis of thioesters, up to then essentially impossible with hydrolases. A wide range of thiol and thiophenol can now be converted. Particularly intriguing was that even CoA could be converted to acetyl-CoA. This was possible although the reaction times were long. However, the Ser11Cys MsAcT did not hydrolyse the product, allowing these long reaction times. The enzyme in this case utilised a different tunnel to the active side, allowing the large substrate to enter. With the Ser11Cys mutant it was also possible to convert amines into amides. Particularly interesting is the conversion of secondary amines to tertiary amides. This challenge had earlier not been met (Scheme 32). Thus, by a single mutation two major challenges for Green Chemistry have been solved, the straightforward and clean syntheses of thioesters and tertiary amides.<sup>301</sup>

An alternative methodology to synthesise amides in aqueous media has recently been introduced by Flitsch and co-workers.<sup>302</sup> Based on a careful analysis of the catalytic mechanism of carboxylic acid reductases (CARs, *vide infra*) the authors hypothesised that CARs, next to the ATP- and NADPH-driven reduction of carboxylic acids, should also be able to catalyse the

amidation of enzyme-bound and ATP-activated carboxylic acids (Scheme 33). A broad range of carboxylic acids and amine nucleophiles could be converted in high yields using this creative exploitation of mechanistic understanding!

**2.3.1.2. Hydrolysis of PET.** The application of esterases, lipases and amidases in polymer chemistry was for a long time focussed on the synthesis of polymers. The hydrolysis of polyesters or polyamides was much less investigated.<sup>12</sup> This is actually surprising as the hydrolysis of esters and amides in water should be straightforward. However, the hydrophobic surface properties and the low accessibility of the functional groups of the polymers essentially prevented this. While it is highly important that polymers are not biodegraded when they are applied in building materials and electrical appliances the ever increasing amount of plastic waste does need to be degraded. Indeed, plastics that are intended for short term usage should be designed in a biodegradable manner. Here splitting into the starting materials for recycling as truly new plastic would be of particular interest. This should in particular be possible for plastics with a hydrolysable ester or amide group.<sup>303</sup>

A major step toward polymer degradation and recycling was made when a Polyethylene Terephthalate (PET) degrading bacterium was identified.<sup>304</sup> This, together with earlier work on polymer degrading enzymes, gave a new boost to recycling of PET to the monomers. The natural answer to the difficult accessibility of the functional groups of the polymer was to evolve a swallow active site open along the surface. This type of active site already existed in cutinases, enzymes that hydrolyse waxes on leaves. Both the naturally evolved PETase and enzymes that were evolved in the laboratory proved interesting starting points for PET recycling. Very recently an enzyme was reported that was successfully evolved for this purpose. This mutated cutinase is highly suitable for the rapid hydrolysis of amorphous PET at relatively high temperatures (72 °C). It is important that the PET is amorphous in structure as crystalline PET is much more difficult to hydrolyse. At these relatively high temperatures the cutinase mutant rapidly hydrolyses post-consumer waste PET to approx. 90%, releasing terephthalic acid (Scheme 34). The high rate of hydrolysis is essential as PET otherwise crystallises under the reaction conditions. The obtained terephthalic acid was utilised to again prepare virgin PET of the same quality as before. While this does introduce two additional steps into the recycling it also means that always



**Scheme 31** MsAcT catalyses the formation of esters and amides in water.







**Scheme 32** The mutation of the catalytic Ser11 to Cys enables the synthesis of thioesters, including acetyl-Co-A as well as the synthesis of tertiary amides.



**Scheme 33** Turning a carboxylic acid reductase into a carboxylic acid amidase.

pristine polymer is (re-)generated. If the polymer is recycled as such the quality quickly degrades and down-cycling rather than re-cycling takes place.<sup>305,306</sup>

**2.3.1.3. Cyanide-free nitrile synthesis.** The selective hydrolysis of nitriles to amides or acids is well-established industrial practice. The enzymes utilised for this, nitrilases and nitrile hydratases cannot be used in reverse. However, more recently a

new type of enzyme was described that can convert aldoximes into nitriles. These aldoxime dehydratases (Oxd) contain a heme iron centre to which the aldoxime coordinates with its nitrogen atom. Subsequent elimination of the hydroxy group, induced by the catalytic cascade of Arg His Ser and enabled by the oxidation of Fe(II) to Fe(IV) is followed by the release of carbonyl hydrogen as proton with simultaneous reduction of the Fe back to Fe(II) and release of the nitrile from the active site.<sup>307,308</sup>

The Oxd can be employed in whole cells with the separately prepared aldoxime or the aldoxime can be generated *in situ* and then directly converted to the desired nitrile (Scheme 35). Oxd have been demonstrated to be enantioselective and they distinguish between *E* and *Z* aldoximes. Their application for the preparation of dinitriles, relevant for the polymer industry, has been demonstrated. Whole cell preparations have successfully been utilised in flow, demonstrating the versatility of these enzymes.<sup>308–310</sup>

### 2.3.2 Oxidation reactions

**2.3.2.1 Alcohol oxidation to aldehydes.** Enzyme-catalysed alcohol oxidation to aldehydes, relevant compounds for the flavour and fragrance industry, can be carried out by the classic nicotinamide-dependent alcohol dehydrogenases (ADHs).<sup>31</sup>



**Scheme 34** A cutinase mutant evolved in the laboratory for the hydrolysis of PET can hydrolyse approx. 90% of post-consumer waste PET at elevated temperature.





**Scheme 35** Application of Oxd to prepare nitriles from aldehydes. The initial preparation of the aldoxime is not catalysed but can be performed *in situ*.



**Scheme 36** AlcOx-Catalysed oxidation of alcohols to aldehydes.

However, recent renewed interest combined with extensive mining of enzymes led to the discovery and applications of interesting flavin-dependent (FAD-AlcOx) and copper-radical alcohol oxidases (CRO-AlcOx).<sup>311,312</sup> A major attraction of AlcOx is their lack of dependence on the NAD(P) cofactor, simply using molecular oxygen as a terminal electron acceptor. These AlcOx enzymes allow access to terpenes and derivatives used in the fragrance industry.<sup>311</sup> Over-oxidation to the carboxylic acid remains minor and catalase is used to remove the formed hydrogen peroxide in solution (Scheme 36).

**2.3.2.3 C=C epoxidation.** Asymmetric epoxidation of alkenes provides access to valuable chiral epoxide building blocks. Established with P450-BM3, epoxidation of styrenes and terpenoids occurs with high chemo-, regio-, and stereoselectivity.<sup>313</sup> In addition, unspecific peroxygenases (UPOs) and flavoprotein styrene monooxygenases (SMOs)<sup>171</sup> allow for complementary substrate scope towards steroid and aromatic products (Scheme 37). In particular, a new clade of SMO that catalyse the epoxidation

of alkenes now complements the already extensive (*S*)-selective SMO family to give access to the corresponding (*R*)-chiral epoxides.<sup>314</sup>

Preparative-scale (up to the kg-range) whole-cell-catalysed epoxidations with SMOs have been demonstrated by Schmid and co-workers.<sup>315,316</sup>

**2.3.2.4 Oxidation of sulfur.** Flavoprotein monooxygenases (FPMOs) have been recently reviewed to catalyse a wide variety of reactions ranging from electrophilic oxygenation, electrophilic aromatic substitution, nucleophilic oxygenation, radical mechanisms to miscellaneous reactions.<sup>171</sup> Asymmetric sulfoxidation using an engineered flavoprotein cyclohexane monooxygenase CHMO was demonstrated for the production of the proton-pump inhibitor (*S*)-omeprazole (esomeprazole) with the higher enantiomeric excess (>99%) than its current chemical catalytic counterpart (Scheme 38).<sup>317</sup>

Asymmetric sulfoxidation can also be catalysed by flavoprotein SMOs mentioned above and allow for complementary selectivity and substrate scope.<sup>318,319</sup>

**2.3.3 Reduction reactions.** The stereoselective reduction of a prochiral ketone, imine or substituted alkene, enables access to chiral products, and furthermore the chemoselective enzymatic reduction of carboxylic acid is highly attractive to obtain aldehydes. These reactions require a strong reductant, which explains why 80% of oxidoreductases are dependent on the nicotinamide adenine dinucleotide cofactor (NAD(P)H).

**2.3.3.1. Reduction of ketones and aldehydes to alcohol.** The most widely applied oxidoreductase enzymes for reduction in organic chemistry are the ketoreductases (KREDs), which catalyse the reversible asymmetric hydrogenation of ketones to the corresponding alcohol (Scheme 39).<sup>32</sup> The name is usually interchanged between the typical zinc-dependent medium-chain dehydrogenase family, represented by the horse liver ADH,<sup>320,321</sup> and short-chain dehydrogenase ADHs such as from *Lactobacillus kefir*.<sup>322,323</sup> Long-chain dehydrogenases and aldo-ketoreductases remain underused in biocatalytic applications.<sup>322</sup> The dependence of



**Scheme 37** Asymmetric epoxidation of alkenes can be catalysed by P450-BM3, SMO or UPO.






**Scheme 38** CHMO-Catalysed asymmetric sulfoxidation to afford esomeprazole in high yield and enantiomeric excess.

KREDs on stoichiometric amounts of NADH or phosphorylated form NADPH as a reductant can be overcome with efficient and established *in situ* recycling systems (Scheme 39). Most common systems either use the same KRED and a sacrificial co-substrate (*e.g.* isopropanol) in large excess, or couple another oxidoreductase enzyme such as glucose dehydrogenase (GDH), formate dehydrogenase (FDH) or phosphite dehydrogenase (PDH)

with their corresponding substrate (glucose, carbonate or phosphite).<sup>154,324</sup>

The asymmetric reduction of prochiral ketones using ADHs has evolved to a mainstream robust and reliable technology with examples reaching a variety of chemical motifs for the chemical industry.<sup>325</sup> ADHs have been implemented for the asymmetric reduction of prochiral ketones in the production of blockbuster pharmaceutical drugs such as Lipitor (atorvastatin), affording high standards for enantiopurity.<sup>326,327</sup> Several stereoselective ADH-catalysed ketone reductions have led to the production of chiral intermediates and pharmaceutical products such as montelukast,<sup>327</sup> emend,<sup>328</sup> sulopenem,<sup>329</sup> at industrial scale (Scheme 40).

KRED enzymes are now commonly used for the reduction of aromatic, aliphatic and cyclic ketones to their corresponding chiral alcohol with exquisite selectivity. These enzymes generally display a wide substrate scope and high selectivity towards the desired enantiomer thanks to available stereocomplementary KREDs, which also allows for deracemisation and stereo-inversion processes.<sup>330,331</sup> The challenging reduction of bulky



**Scheme 39** KRED-Catalysed reduction of an aldehyde or ketone to alcohol (left), with available NAD(P)H enzymatic cofactor recycling systems (right).



**Scheme 40** KRED/ADH-Catalysed reduction of ketones or aldehydes. Examples of chiral alcohols produced on large scale with high enantiopurity; drug name in brackets.



substituted ketones has now been addressed as more enzymes are being discovered and evolved to tolerate these substrates such as the montelukast example. KREDs can also be employed to reduce aldehydes and obtain chiral substituted alcohols in a dynamic kinetic resolution system.<sup>332,333</sup>

**2.3.3.2. Reductive amination and transamination of aldehydes and ketones.** The reductive amination of ketones leading to chiral amines can now be achieved by different family of enzymes developed in the 2010's. Thus, imine reductases (IREDs),<sup>334–336</sup> amine dehydrogenases (AmDHs)<sup>337–341</sup> and reductive aminases (RedAms)<sup>342,343</sup> catalyse the formation of the imine and its subsequent reduction (Scheme 41).<sup>344,345</sup> These reductive enzymes, together with amino acid dehydrogenases (AaDHs) that transform keto acids to amino acids, and PLP-dependent transaminases (TAs) that catalyse transamination, give access to primary, secondary and tertiary amines and have been applied on gram to kilogram scale. Transaminases in particular have been used in many processes already, for example in the synthesis of sitagliptin.<sup>346,347</sup>

IREDs also have the ability to catalyse the reduction of (usually cyclic) imines formed *in situ* to the corresponding amine. Turner and co-workers recently explored the structure–activity relationship of IREDs, which seem to be highly dependent on the substrate thus does not allow to predict the outcome based on an IRED and substrate pair.<sup>348</sup>

In order to shift the equilibrium to the desired amine product, AmDHs, IREDs and TAs require an excess of amine

donor to reach full conversion, whereas the recently discovered RedAms do not, and can generate secondary and tertiary amines with stoichiometric carbonyl and amine substrates.<sup>342,345,349</sup>

Seminal work by Turner and co-workers showed that chiral amines can also be obtained using flavin-dependent monoamine oxidases (MAOs) in a chemo-enzymatic process, by oxidising amines to imines with concomitant non-selective chemical reduction of the imine.<sup>350</sup>

**2.3.3.3. Carboxylic acid reduction to aldehyde.** The chemical reduction of carboxylic acids to aldehydes is not trivial, usually requiring a strong reductant, and the desired aldehyde tends to be further reduced to the alcohol. The discovery of carboxylic acid reductases (CARs) has allowed the reduction of mostly aromatic carboxylic acids and fatty acids under mild reaction conditions through activation of the carboxylate with ATP, forming a thioester further reduced by NADPH.<sup>351,352</sup>


The attractiveness of these enzymes for wider applications *in vitro* remains limited due to their requirement for ATP, hence their use in microbial cells. Nevertheless, CAR-catalysed reduction of carboxylic acids are relevant to obtain volatile aldehyde products for the flavour and fragrance industry, or intermediate building blocks in cascade reactions (Scheme 42).<sup>351,352</sup> Examples include the production of amines, diamines, aldol compounds and vanillin.<sup>351</sup> Recently CARs were even used for amide bond formation using amines bypassing the NADPH reduction step (see above),<sup>302,353</sup> thus expanding the utility of these enzymes on carboxylic acid functional group interconversion.



**Scheme 41** (A) AmDH-, RedAm-, IRED-Catalysed reductive amination and TA-catalysed transamination with ammonia or alkyl amines. (B) IRED-catalysed reduction of imines. Selected examples of chiral amine products.







**Scheme 42** CAR-catalysed reduction of aromatic and aliphatic carboxylic acids to aldehydes further used as building blocks. MnCAR: from *M. neoaurum*; NiCAR: *N. iowensis*; MmCAR: from *M. marinum*; MsCAR: from *M. smegmatis*.

**2.3.3.4 Asymmetric C=C reduction.** The enzymatic asymmetric hydrogenation catalysed by flavin-dependent Old Yellow Enzyme ene reductases (EREDs), first identified by Warburg in 1932, has clearly been in the lead in the past decade. In particular, OYE were proven to catalyse highly regio-, chemo- and stereoselective reduction of activated alkenes in a *trans*-addition fashion.<sup>354,355</sup> The alkenes substrates typically require an electron withdrawing group such as a carbonyl, nitro, or nitrile (Scheme 43).


EREDs are promising catalysts, allowing for hydrogenation reactions without the use of a palladium catalyst or hydrogen gas, under mild reaction conditions in water. This does bring along the challenge of substrate solubility, which has been addressed using biphasic systems and co-solvents.<sup>356</sup> In addition, these enzymes display cofactor promiscuity due to their prosthetic flavin cofactor laying in a TIM-barrel motif, allowing access to not only both natural NAD(P)H, but also artificial analogues,<sup>357,358</sup> and electron mediators.<sup>359</sup> Various chiral building blocks and products have already been scaled-up, such as (*R*)-profens,

(*R*)-citronellal, a valuable intermediate for the synthesis of menthol, and dihydrocarvone (Scheme 43).<sup>32</sup>

OYEs can also catalyse the reduction of alkynes in a selective fashion, obtaining the *trans*-alkene.<sup>360</sup> If the reaction is left longer then full reduction to the alkane is observed. The additional use of light with these enzymes has recently unfolded different types of activities such as dehalogenation, and intra- and intermolecular carbon-carbon bond formation.<sup>361,362</sup>


## 2.4 Multi-enzyme cascades – a few examples highlighting the potential

Multi-enzyme cascades are the essence of life. All metabolic routes are such cascades, circular in the case of the citric acid cycle and the many cycles known from the huge posters that decorate many (bio)chemists offices and is today an online tool (<https://web.expasy.org/pathways/>). In all cases the cascades keep concentrations of all intermediates low, thus avoiding inhibition of the enzymes. In particular the cascades that lead to secondary metabolites have attracted much attention as they




**Scheme 43** ERED-Catalysed asymmetric hydrogenation of activated C=C bonds to the corresponding (chiral) alkane building block or final product. EWG = electron withdrawing group: aldehyde, ketone, carboxylic acid, ester, nitrile, nitro.





**Scheme 44** *In vitro* biosynthesis of the corrin ring of vitamin B<sub>12</sub>. In a glass flask 12 enzymes perform the 17 step biosynthesis with excellent yield.



**Scheme 45** Enzyme-catalysed synthetic route for the production of the drug islatravir developed by Merck. DERA = deoxyribose-phosphate aldolase; PPM = phosphopentomutase; PNP = purine nucleoside phosphorylase.

often have interesting biological activities. These cascades were therefore from the very beginning of biosynthetic studies a focus of attentions. A first milestone was the synthesis of the corrin scaffold in 1994. Starting from 5-aminolevulinic acid, utilizing 12 biosynthetic enzymes 17 steps were catalysed, creating 9 stereocentres and with an overall yield of 20% hydrogenobyric acid was formed (Scheme 44). This is a key intermediate for vitamin B<sub>12</sub>. It can be converted into the vitamin with just two further steps. All the elegance of the earlier chemical synthesis fades besides this achievement.<sup>363,364</sup>

Ever since then cascades of enzyme-catalysed reactions have attracted attention.<sup>365–369</sup> Several arguments are in favour of this approach. Cascade reactions are much closer to the natural conditions under which enzymes operate, relatively low substrate and product concentrations throughout the cascade occur, as only the starting material and the final product will be present in high concentrations. Furthermore the large number of steps allows to plan the synthesis in such a manner that the last step also constitutes a thermodynamically favourable reaction, shifting the overall equilibrium towards the product side. This is the case in the hydrogenobyric acid synthesis and the example below. Additionally, cofactor recycling is much easier in cascades, in particular if they involve oxidation and reduction steps that can be balanced.

Recent reviews compiled the combination of multiple enzymes in sequence, enabling access to complex functionalised molecules starting from basic starting materials.<sup>370,371</sup> An example of a multi-enzymatic cascade was demonstrated by Merck for the production of the drug islatravir (Scheme 45).<sup>21</sup> The shift of the equilibrium towards the product was achieved by converting the phosphate released in the PNP catalysed step in an irreversible additional, removal step.

### 3. Conclusions

Closing in on almost two centuries since the discovery of emulsin, biocatalysis has increasing impact the field of organic synthesis by providing alternative methods for the synthesis of many classes of compounds with unrivalled selectivity. The first wave of biocatalysis was rather limited in the number of reactions that it enabled. Often only a single enzyme was available for the desired reaction. This landscape has completely changed. The second and third waves ensured that today biocatalysis is based on an understanding of the enzymes, including their scaffolds, which allows rapid identification of countless variations of a specific enzymatic activity, making a catalyst available for essentially all substrates with the functional group the synthetic chemist wishes to modify. More importantly, new reactions can be catalysed that were before-hand considered outside the scope of enzymes. This, in combination with an improved understanding of kinetics and thermodynamics governing the reactions, today allow the fast, efficient and clean synthesis of very complex structures under very mild conditions.

New types of biocatalytic reactions remain to be unravelled with already known or soon to be discovered enzymes that would allow access to further classes of molecules. With this, biocatalysis is part of the many waves of change in chemistry.

### Author contributions

All authors equally contributed to the conceptualization, visualization, writing of the original draft and in the final review and editing.



## Conflicts of interest

There are no conflicts of interest to declare.

## References

- 1 F. Wöhler and J. Liebig, *Ann. Pharm.*, 1837, **22**, 1–24.
- 2 P. M. D. Collins, *Platinum Met. Rev.*, 1986, **30**, 141–146.
- 3 E. Fischer, *Ber. Dtsch. Chem. Ges.*, 1894, **27**, 2985–2993.
- 4 L. Rosenthaler, *Biochem. Z.*, 1908, **14**, 238–253.
- 5 U. T. Bornscheuer, G. W. Huisman, R. J. Kazlauskas, S. Lutz, J. C. Moore and K. Robins, *Nature*, 2012, **485**, 185–194.
- 6 J. Sukumaran and U. Hanefeld, *Chem. Soc. Rev.*, 2005, **34**, 530–542.
- 7 U. Hanefeld and L. Lefferts, *Catalysis: An Integrated Textbook for Students*, Wiley-VCH, 2017.
- 8 K. Faber, *Biotransformations in Organic Chemistry*, Springer Verlag, 2018.
- 9 K. Hult and P. Berglund, *Trends Biotechnol.*, 2007, **25**, 231–238.
- 10 H. E. Schoemaker, D. Mink and M. G. Wubbolds, *Science*, 2003, **299**, 1694–1697.
- 11 A. Schmid, J. S. Dordick, B. Hauer, A. Kiener, M. Wubbolds and B. Witholt, *Nature*, 2001, **409**, 258–268.
- 12 E. M. M. Abdelraheem, H. Busch, U. Hanefeld and F. Tonin, *React. Chem. Eng.*, 2019, **4**, 1878–1894.
- 13 M. A. Findeis and G. M. Whitesides, *J. Org. Chem.*, 1987, **52**, 2838–2848.
- 14 A. M. Klivanov, *Nature*, 2001, **409**, 241–246.
- 15 L. E. Zetzsche and A. R. H. Narayan, *Nat. Rev. Chem.*, 2020, **4**, 334–346.
- 16 C. K. Winkler, J. H. Schrittwieser and W. Kroutil, *ACS Cent. Sci.*, 2021, **7**, 55–71.
- 17 E. Romero, B. S. Jones, B. N. Hogg, A. Rué Casamajo, M. A. Hayes, S. L. Flitsch, N. J. Turner and C. Schnepel, *Angew. Chem., Int. Ed.*, 2021, **60**, 16824–16855.
- 18 F. H. Arnold, *Angew. Chem., Int. Ed.*, 2019, **58**, 14420–14426.
- 19 M. M. C. H. van Schie, J. D. Spörling, M. Bocola, P. Domínguez de María and D. Rother, *Green Chem.*, 2021, **23**, 3191–3206.
- 20 U. Markel, L. L. Zhu, V. J. Frauenkron-Machedjou, J. Zhao, M. Bocola, M. D. Davari, K. E. Jaeger and U. Schwaneberg, *Catalysts*, 2017, **7**, 142.
- 21 M. A. Huffman, A. Fryszkowska, O. Alvizo, M. Borra-Garske, K. R. Campos, K. A. Canada, P. N. Devine, D. Duan, J. H. Forstater, S. T. Grosser, H. M. Halsey, G. J. Hughes, J. Jo, L. A. Joyce, J. N. Kolev, J. Liang, K. M. Maloney, B. F. Mann, N. M. Marshall, M. McLaughlin, J. C. Moore, G. S. Murphy, C. C. Nawrat, J. Nator, S. Novick, N. R. Patel, A. Rodriguez-Granillo, S. A. Robaire, E. C. Sherer, M. D. Truppo, A. M. Whittaker, D. Verma, L. Xiao, Y. Xu and H. Yang, *Science*, 2019, **366**, 1255–1259.
- 22 X. Q. Meng, L. Yang, Y. Liu, H. L. Wang, Y. L. Shen and D. Z. Wei, *ChemCatChem*, 2021, **13**, 3340–3349.
- 23 U. Hanefeld, L. Gardossi and E. Magner, *Chem. Soc. Rev.*, 2009, **38**, 453–468.
- 24 R. A. Sheldon and S. van Pelt, *Chem. Soc. Rev.*, 2013, **42**, 6223–6235.
- 25 A. Basso and S. Serban, *Mol. Catal.*, 2019, **479**, 35–54.
- 26 P. De Santis, L.-E. Meyer and S. Kara, *React. Chem. Eng.*, 2020, **5**, 2155–2184.
- 27 V. D. Jäger, R. Lamm, K. Küsters, G. Ölcücü, M. Oldiges, K. E. Jaeger, J. Büchs and U. Krauss, *Appl. Microbiol. Biotechnol.*, 2020, **104**, 7313–7329.
- 28 W. B. Liang, P. Wied, F. Carraro, C. J. Sumby, B. Nidetzky, C. K. Tsung, P. Falcato and C. J. Doonan, *Chem. Rev.*, 2021, **121**, 1077–1129.
- 29 D. Videira-Quintela, O. Martin and G. Montalvo, *Microchem. J.*, 2021, **167**, 106318.
- 30 C. Ortiz, M. L. Ferreira, O. Barbosa, J. C. S. dos Santos, R. C. Rodrigues, A. Berenguer-Murcia, L. E. Briand and R. Fernandez-Lafuente, *Catal. Sci. Technol.*, 2019, **9**, 2380–2420.
- 31 J. J. Dong, E. Fernández-Fueyo, F. Hollmann, C. E. Paul, M. Pesic, S. Schmidt, Y. H. Wang, S. Younes and W. Y. Zhang, *Angew. Chem., Int. Ed.*, 2018, **57**, 9238–9261.
- 32 F. Hollmann, D. J. Opperman and C. E. Paul, *Angew. Chem., Int. Ed.*, 2021, **60**, 5644–5665.
- 33 R. O. M. A. de Souza, L. S. M. Miranda and U. T. Bornscheuer, *Chem. – Eur. J.*, 2017, **23**, 12040–12063.
- 34 K. Fesko and M. Gruber-Khadjawi, *ChemCatChem*, 2013, **5**, 1248–1272.
- 35 M. Brovetto, D. Gamenara, P. S. Mendez and G. A. Seoane, *Chem. Rev.*, 2011, **111**, 4346–4403.
- 36 D. Rother and S. Malzacher, *Nat. Catal.*, 2021, **4**, 92–93.
- 37 R. Roddan, J. M. Ward, N. H. Keep and H. C. Hailes, *Curr. Opin. Chem. Biol.*, 2020, **55**, 69–76.
- 38 P. Bracco, H. Busch, J. von Langermann and U. Hanefeld, *Org. Biomol. Chem.*, 2016, **14**, 6375–6389.
- 39 M. Liu, D. Wei, Z. X. Wen and J. B. Wang, *Front. Bioeng. Biotechnol.*, 2021, **9**, 653682.
- 40 M. Winkler, A. Glieder and K. Steiner, in *Comprehensive Chirality*, ed. E. M. Carreira and H. Yamamoto, Elsevier, Amsterdam, 2012, pp. 350–371.
- 41 R. Wiedner, H. Schwab and K. Steiner, *Green Biocatalysis*, 2016, pp. 603–628.
- 42 H. C. Hailes, D. Rother, M. Muller, R. Westphal, J. M. Ward, J. Pleiss, C. Vogel and M. Pohl, *FEBS J.*, 2013, **280**, 6374–6394.
- 43 M. Pohl, C. Wechsler and M. Meller, in *Science of Synthesis Biocatalysis in Organic Synthesis 2*, ed. K. Faber, W.-D. Fessner and N. J. Turner, Georg Thieme Verlag, Stuttgart, 2014, pp. 93–127.
- 44 F. Motojima, A. Izumi, A. Nuyler, Z. Y. Zhai, M. Dadashpour, S. Shichida, T. Yamaguchi, S. Nakano and Y. Asano, *FEBS J.*, 2021, **288**, 1679–1695.
- 45 U. Hanefeld, *Chem. Soc. Rev.*, 2013, **42**, 6308–6321.
- 46 J. Holt and U. Hanefeld, *Curr. Org. Synth.*, 2009, **6**, 15–37.
- 47 T. Purkharthofer, K. Gruber, M. Gruber-Khadjawi, K. Waich, W. Skranc, D. Mink and H. Griengl, *Angew. Chem., Int. Ed.*, 2006, **45**, 3454–3456.



- 48 D. H. S. Rao, A. Chatterjee and S. K. Padhi, *Org. Biomol. Chem.*, 2021, **19**, 322–337.
- 49 A. M. C. H. van den Nieuwendijk, A. B. T. Ghisaidoobe, H. S. Overkleeft, J. Brussee and A. van der Gen, *Tetrahedron*, 2004, **60**, 10385–10396.
- 50 D. J. Vugts, L. Veum, K. al-Mafraji, R. Lemmens, R. F. Schmitz, F. J. J. de Kanter, M. B. Groen, U. Hanefeld and R. V. A. Orru, *Eur. J. Org. Chem.*, 2006, 1672–1677.
- 51 A. Nuylert, M. Nakabayashi, T. Yamaguchi and Y. Asano, *Acs Omega*, 2020, **5**, 27896–27908.
- 52 M. Dadashipour, Y. Ishida, K. Yamamoto and Y. Asano, *Proc. Natl. Acad. Sci. U. S. A.*, 2015, **112**, 10605–10610.
- 53 Y. Kuwahara, T. Yamaguchi, Y. Ichiki, T. Tanabe and Y. Asano, *Sci. Nat.*, 2017, **104**, 19.
- 54 I. Hajnal, A. Lyskowski, U. Hanefeld, K. Gruber, H. Schwab and K. Steiner, *FEBS J.*, 2013, **280**, 5815–5828.
- 55 F. Vertregt, G. Torrelo, S. Trunk, H. Wiltse, W. R. Hagen, U. Hanefeld and K. Steiner, *ACS Catal.*, 2016, **6**, 5081–5085.
- 56 R. Wiedner, B. Kothbauer, T. Pavkov-Keller, M. Gruber-Khadjawi, K. Gruber, H. Schwab and K. Steiner, *ChemCatChem*, 2015, **7**, 325–332.
- 57 B. J. Jones, R. L. Evans, N. J. Mylrea, D. Chaudhury, C. Luo, B. Guan, C. T. Pierce, W. R. Gordon, C. M. Wilmot and R. J. Kazlauskas, *PLoS One*, 2020, **15**, e0235341.
- 58 S. K. Padhi, R. Fujii, G. A. Legatt, S. L. Fossum, R. Berchtold and R. J. Kazlauskas, *Chem. Biol.*, 2010, **17**, 863–871.
- 59 M. P. van der Helm, P. Bracco, H. Busch, K. Szymanska, A. B. Jarzebski and U. Hanefeld, *Catal. Sci. Technol.*, 2019, **9**, 1189–1200.
- 60 A. Brahma, B. Musio, U. Ismayilova, N. Nikbin, S. B. Kamptmann, P. Siegert, G. E. Jeromin, S. V. Ley and M. Pohl, *Synlett*, 2016, 262–266.
- 61 R. Kluger and K. Tittmann, *Chem. Rev.*, 2008, **108**, 1797–1833.
- 62 D. Meyer, P. Neumann, R. Ficner and K. Tittmann, *Nat. Chem. Biol.*, 2013, **9**, 488–U484.
- 63 S. Dai, L. M. Funk, F. R. von Pappenheim, V. Sautner, M. Paulikat, B. Schroder, J. Uranga, R. A. Mata and K. Tittmann, *Nature*, 2019, **573**, 609–613.
- 64 M. Pareek, Y. Reddi and R. B. Sunoj, *Chem. Sci.*, 2021, **12**, 7973–7992.
- 65 G. Goetz, P. Iwan, B. Hauer, M. Breuer and M. Pohl, *Biotechnol. Bioeng.*, 2001, **74**, 317–325.
- 66 Y. Kobori, D. C. Myles and G. M. Whitesides, *J. Org. Chem.*, 1992, **57**, 5899–5907.
- 67 S. R. Marsden, L. Gjonaj, S. J. Eustace and U. Hanefeld, *ChemCatChem*, 2017, **9**, 1808–1814.
- 68 R. Westphal, C. Vogel, C. Schmitz, J. Pleiss, M. Muller, M. Pohl and D. Rother, *Angew. Chem., Int. Ed.*, 2014, **53**, 9376–9379.
- 69 L. Wang, W. Song, B. Wang, Y. Zhang, X. Xu, J. Wu, C. Gao, J. Liu, X. Chen, J. Chen and L. Liu, *ACS Catal.*, 2021, **11**, 2808–2818.
- 70 V. Erdmann, T. Sehl, I. Frindi-Wosch, R. C. Simon, W. Kroutil and D. Rother, *ACS Catal.*, 2019, **9**, 7380–7388.
- 71 Q. Liu, X. Xie, M. Tang, W. Tao, T. Shi, Y. Zhang, T. Huang, Y. Zhao, Z. Deng and S. Lin, *ACS Catal.*, 2021, **11**, 7477–7488.
- 72 X. Chen, Z. Wang, Y. Lou, Y. Peng, Q. Zhu, J. Xu and Q. Wu, *Angew. Chem., Int. Ed.*, 2021, **60**, 9326–9329.
- 73 S. Desnions, R. Faure and S. Bontemps, *ACS Catal.*, 2019, **9**, 9575–9588.
- 74 M. Nattermann, S. Burgener, P. Pfister, A. Chou, L. Schulz, S. H. Lee, N. Paczia, J. Zarzycki, R. Gonzalez and T. J. Erb, *ACS Catal.*, 2021, **11**, 5396–5404.
- 75 J. L. Galman, D. Steadman, S. Bacon, P. Morris, M. E. B. Smith, J. M. Ward, P. A. Dalby and H. C. Hailes, *Chem. Commun.*, 2010, **46**, 7608–7610.
- 76 A. Cazares, J. L. Galman, L. G. Crago, M. E. B. Smith, J. Strafford, L. Rios-Solis, G. J. Lye, P. A. Dalby and H. C. Hailes, *Org. Biomol. Chem.*, 2010, **8**, 1301–1309.
- 77 H. Casajus, A. Lagarde, M. Lereboure, T. D. Miguel, L. Nauton, V. Thery, W. D. Fessner, N. Duguet, F. Charmantray and L. Hecquet, *ChemCatChem*, 2020, **12**, 5772–5779.
- 78 T. Saravanan, S. Junker, M. Kickstein, S. Hein, M. K. Link, J. Ranglack, S. Witt, M. Lorilliere, L. Hecquet and W. D. Fessner, *Angew. Chem., Int. Ed.*, 2017, **56**, 5358–5362.
- 79 S. R. Marsden, D. G. G. McMillan and U. Hanefeld, *Int. J. Mol. Sci.*, 2020, **21**, 8641.
- 80 P. Clapés, *Green Biocatalysis*, 2016, pp. 267–306.
- 81 E. Busto, *ChemCatChem*, 2016, **8**, 2589–2598.
- 82 S. R. Marsden, L. Mestrom, D. G. G. McMillan and U. Hanefeld, *ChemCatChem*, 2020, **12**, 426–437.
- 83 K. Fesko, C. Reisinger, J. Steinreiber, H. Weber, M. Schurmann and H. Griengl, *J. Mol. Catal. B: Enzym.*, 2008, **52–53**, 19–26.
- 84 K. Shibata, K. Shingu, V. P. Vassilev, K. Nishide, T. Fujita, M. Node, T. Kajimoto and C. H. Wong, *Tetrahedron Lett.*, 1996, **37**, 2791–2794.
- 85 S. R. Marsden, L. Mestrom, H. J. Wijma, S. J. Noordam, D. G. G. McMillan and U. Hanefeld, *ChemCatChem*, 2021, **13**, 2530–2536.
- 86 M. Haridas, E. M. M. Abdelraheem and U. Hanefeld, *Appl. Microbiol. Biotechnol.*, 2018, **102**, 9959–9971.
- 87 L. R. Chen, D. P. Dumas and C. H. Wong, *J. Am. Chem. Soc.*, 1992, **114**, 741–748.
- 88 H. J. M. Gijzen and C. H. Wong, *J. Am. Chem. Soc.*, 1994, **116**, 8422–8423.
- 89 M. Dick, R. Hartmann, O. H. Weiergraber, C. Bisterfeld, T. Classen, M. Schwarten, P. Neudecker, D. Willbold and J. Pietruszka, *Chem. Sci.*, 2016, **7**, 4492–4502.
- 90 S. Voutilainen, M. Heinonen, M. Andberg, E. Jokinen, H. Maaheimo, J. Paakkonen, N. Hakulinen, J. Rouvinen, H. Lahdesmaki, S. Kaski, J. Rousu, M. Penttila and A. Koivula, *Appl. Microbiol. Biotechnol.*, 2020, **104**, 10515–10529.
- 91 M. Haridas, C. Bisterfeld, L. Chen, S. R. Marsden, F. Tonin, R. Medici, A. Iribarren, E. Lewkowicz, P. L. Hagedoorn, U. Hanefeld and E. Abdelraheem, *Catalysts*, 2020, **10**, 883.
- 92 C. Bisterfeld, T. Classen, I. Kubler, B. Henssen, A. Metz, H. Gohlke and J. Pietruszka, *PLoS One*, 2016, **11**, e0156525.
- 93 X. C. Jiao, J. Pan, G. C. Xu, X. D. Kong, Q. Chen, Z. J. Zhang and J. H. Xu, *Catal. Sci. Technol.*, 2015, **5**, 4048–4054.





- 94 S. H. Zhang, J. Bramski, M. Tutus, J. Pietruszka, A. Boker and S. Reinicke, *ACS Appl. Mater. Interfaces*, 2019, **11**, 34441–34453.
- 95 B. Grabner, Y. Pokhilchuk and H. Gruber-Woelfler, *Catalysts*, 2020, **10**, 137.
- 96 P. Hoyos, V. Pace and A. R. Alcantara, *Catalysts*, 2019, **9**, 260.
- 97 M. Schürmann, *Industrial Enzyme Applications*, 2019, pp. 385–403.
- 98 J. J. Liu, C. C. Hsu and C. H. Wong, *Tetrahedron Lett.*, 2004, **45**, 2439–2441.
- 99 A. Svarc, M. Fekete, K. Hernandez, P. Clapes, Z. F. Blazevec, A. Szekrenyi, D. Skendrovic, D. Vasic-Racki, S. J. Charnock and A. V. Presecki, *Chem. Eng. Sci.*, 2021, **231**, 116312.
- 100 A. Svarc, Z. F. Blazevec, D. Vasic-Racki, S. J. Charnock and A. V. Presecki, *Chem. Eng. Res. Des.*, 2020, **164**, 35–45.
- 101 K. Pradhan and S. S. Kulkarni, *Eur. J. Org. Chem.*, 2020, 6819–6830.
- 102 C. C. Yu and S. G. Withers, *Adv. Synth. Catal.*, 2015, **357**, 1633–1654.
- 103 U. Kragl, D. Gygax, O. Ghisalba and C. Wandrey, *Angew. Chem., Int. Ed. Engl.*, 1991, **30**, 827–828.
- 104 V. R. L. J. Bloemendal, S. J. Moons, J. J. A. Heming, M. Chayoua, O. Niesink, J. C. M. van Hest, T. J. Boltje and F. P. J. T. Rutjes, *Adv. Synth. Catal.*, 2019, **361**, 2443–2447.
- 105 M. T. de Martino, F. Tonin, V. R. L. J. Bloemendal, U. Hanefeld, F. P. J. T. Rutjes and J. C. M. van Hest, *RSC Adv.*, 2021, **11**, 21857–21861.
- 106 M. Mahmoudian, D. Noble, C. S. Drake, R. F. Middleton, D. S. Montgomery, J. E. Piercey, D. Ramlakhan, M. Todd and M. J. Dawson, *Enzyme Microb. Technol.*, 1997, **20**, 393–400.
- 107 E. Masai, Y. Katayama and M. Fukuda, *Biosci. Biotechnol. Biochem.*, 2007, **71**, 1–15.
- 108 D. Rea, R. Hovington, J. F. Rakus, J. A. Gerlt, V. Fulop, T. D. H. Bugg and D. I. Roper, *Biochemistry*, 2008, **47**, 9955–9965.
- 109 R. W. Eaton and P. J. Chapman, *J. Bacteriol.*, 1992, **174**, 7542–7554.
- 110 J. Fang, D. Hait, M. Head-Gordon and M. C. Y. Chang, *Angew. Chem., Int. Ed.*, 2019, **58**, 11841–11845.
- 111 K. Hernandez, J. Joglar, J. Bujons, T. Parella and P. Clapes, *Angew. Chem., Int. Ed.*, 2018, **57**, 3583–3587.
- 112 S. Bosch, E. Sanchez-Freire, M. L. del Pozo, M. Cesnik, J. Quesada, D. M. Mate, K. Hernandez, Y. Y. Qi, P. Clapes, D. Vasic-Racki, Z. F. Blazevec, J. Berenguer and A. Hidalgo, *ACS Sustainable Chem. Eng.*, 2021, **9**, 5430–5436.
- 113 V. de Berardinis, C. Guerard-Helaine, E. Darii, K. Bastard, V. Helaine, A. Mariage, J. L. Petit, N. Poupard, I. Sanchez-Moreno, M. Stam, T. Gefflaut, M. Salanoubat and M. Lemaire, *Green Chem.*, 2017, **19**, 519–526.
- 114 V. Laurent, L. Goubeyre, A. Uzel, V. Helaine, L. Nauton, M. Traikia, V. de Berardinis, M. Salanoubat, T. Gefflaut, M. Lemaire and C. Guerard-Helaine, *ACS Catal.*, 2020, **10**, 2538–2543.
- 115 S. R. Marsden, L. Mestrom, I. Bento, P. L. Hagedoorn, D. G. G. McMillan and U. Hanefeld, *Adv. Synth. Catal.*, 2019, **361**, 2649–2658.
- 116 T. Suzuki and N. Takizawa, *Biosci. Biotechnol. Biochem.*, 2019, **83**, 1884–1888.
- 117 D. J. Fansher, R. Granger, S. Kaur and D. R. J. Palmer, *ACS Catal.*, 2021, **11**, 6939–6943.
- 118 A. M. Li, L. Cai, Z. Chen, M. Y. Wang, N. Wang, H. Nakanishi, X. D. Gao and Z. J. Li, *Carbohydr. Res.*, 2017, **452**, 108–115.
- 119 V. Laurent, V. Helaine, C. Vergne-Vaxelaire, L. Nauton, M. Traikia, J. L. Petit, M. Salanoubat, V. de Berardinis, M. Lemaire and C. Guerard-Helaine, *ACS Catal.*, 2019, **9**, 9508–9512.
- 120 L. Wen, K. Huang, M. Wei, J. Meisner, Y. Liu, K. Garner, L. Zang, X. Wang, X. Li, J. Fang, H. Zhang and P. G. Wang, *Angew. Chem., Int. Ed.*, 2015, **54**, 12654–12658.
- 121 Z. Ferjancic and R. N. Saicic, *Eur. J. Org. Chem.*, 2021, 3241–3250.
- 122 J. G. Yang, J. T. Li, Y. Men, Y. M. Zhu, Y. Zhang, Y. X. Sun and Y. H. Ma, *Appl. Environ. Microbiol.*, 2015, **81**, 4284–4294.
- 123 L. Babich, A. F. Hartog, L. J. C. van Hemert, F. P. J. T. Rutjes and R. Wever, *ChemSusChem*, 2012, **5**, 2348–2353.
- 124 Z. J. Li, F. Li, L. Cai, Z. Chen, L. Qin and X. D. Gao, *J. Agric. Food Chem.*, 2020, **68**, 1347–1353.
- 125 M. Sugiyama, Z. Y. Hong, W. A. Greenberg and C. H. Wong, *Bioorg. Med. Chem.*, 2007, **15**, 5905–5911.
- 126 A. J. Rigual, J. Cantero, M. Risso, P. Rodriguez, S. Rodriguez, M. Paulino, D. Gamenara and N. Veiga, *Mol. Catal.*, 2020, **495**, 111131.
- 127 X. Garrabou, J. Joglar, T. Parella, R. Crehuet, J. Bujons and P. Clapés, *Adv. Synth. Catal.*, 2011, **353**, 89–99.
- 128 J. A. Castillo, J. Calveras, J. Casas, M. Mitjans, M. P. Vinardell, T. Parella, T. Inoue, G. A. Sprenger, J. Joglar and P. Clapés, *Org. Lett.*, 2006, **8**, 6067–6070.
- 129 M. Sugiyama, Z. Hong, P. H. Liang, S. M. Dean, L. J. Whalen, W. A. Greenberg and C. H. Wong, *J. Am. Chem. Soc.*, 2007, **129**, 14811–14817.
- 130 X. Garrabou, J. Calveras, J. Joglar, T. Parella, J. Bujons and P. Clapés, *Org. Biomol. Chem.*, 2011, **9**, 8430–8436.
- 131 A. L. Concia, L. Gomez, J. Bujons, T. Parella, C. Vilaplana, P. J. Cardona, J. Joglar and P. Clapés, *Org. Biomol. Chem.*, 2013, **11**, 2005–2021.
- 132 M. Gutierrez, T. Parella, J. Joglar, J. Bujons and P. Clapés, *Chem. Commun.*, 2011, **47**, 5762–5764.
- 133 R. Roldán, K. Hernández, J. Joglar, J. Bujons, T. Parella, W. D. Fessner and P. Clapés, *Adv. Synth. Catal.*, 2019, **361**, 2673–2687.
- 134 D. Güclü, A. Szekrenyi, X. Garrabou, M. Kickstein, S. Junker, P. Clapés and W. D. Fessner, *ACS Catal.*, 2016, **6**, 1848–1852.
- 135 M. Widersten, *Enzyme Engineering and Evolution: Specific Enzyme Applications*, 2020, vol. 644, pp. 149–167.
- 136 G. Masdeu, Z. F. Blazevec, S. Kralj, D. Makovec, J. Lopez-Santin and G. Alvaro, *Chem. Eng. Sci.*, 2021, **239**, 116602.





- 137 S. Wang and H. Deng, *Appl. Microbiol. Biotechnol.*, 2021, **105**, 3507–3520.
- 138 K. Fesko, *Appl. Microbiol. Biotechnol.*, 2016, **100**, 2579–2590.
- 139 S. E. Franz and J. D. Stewart, *Adv. Appl. Microbiol.*, 2014, **88**, 57–101.
- 140 Q. J. Chen, X. Chen, Y. F. Cui, J. Ren, W. Lu, J. H. Feng, Q. Q. Wu and D. M. Zhu, *Catal. Sci. Technol.*, 2017, **7**, 5964–5973.
- 141 M. L. Gutierrez, X. Garrabou, E. Agosta, S. Servi, T. Parella, J. Joglar and P. Clapes, *Chem. – Eur. J.*, 2008, **14**, 4647–4656.
- 142 M. Pickl, R. Marin-Valls, J. Joglar, J. Bujons and P. Clapes, *Adv. Synth. Catal.*, 2021, **363**, 2866–2876.
- 143 A. Soler, X. Garrabou, K. Hernández, M. L. Gutiérrez, E. Busto, J. Bujons, T. Parella, J. Joglar and P. Clapés, *Adv. Synth. Catal.*, 2014, **356**, 3007–3024.
- 144 M. D. Patil, G. Grogan and H. Yun, *ChemCatChem*, 2018, **10**, 4797–4818.
- 145 B. R. Lichman, *Nat. Prod. Rep.*, 2021, **38**, 103–129.
- 146 C. S. Jamieson, J. Misa, Y. Tang and J. M. Billingsley, *Chem. Soc. Rev.*, 2021, **50**, 6950–7008.
- 147 J. X. Zhao, D. Mendez-Sanchez, R. Roddan, J. M. Ward and H. C. Hailes, *ACS Catal.*, 2021, **11**, 131–138.
- 148 R. Roddan, G. Gygli, A. Sula, D. Mendez-Sanchez, J. Pleiss, J. M. Ward, N. H. Keep and H. C. Hailes, *ACS Catal.*, 2019, **9**, 9640–9649.
- 149 H. Stecher, M. Teng, B. J. Ueberbacher, P. Remler, H. Schwab, H. Griengl and M. Gruber-Khadjawi, *Angew. Chem., Int. Ed.*, 2009, **48**, 9546–9548.
- 150 M. Teng, H. Stecher, L. Offner, K. Plasch, F. Anderl, H. Weber, H. Schwab and M. Gruber-Khadjawi, *ChemCatChem*, 2016, **8**, 1354–1360.
- 151 I. J. W. McKean, J. C. Sadler, A. Cuertos, A. Frese, L. D. Humphreys, G. Grogan, P. A. Hoskisson and G. A. Burley, *Angew. Chem., Int. Ed.*, 2019, **58**, 17583–17588.
- 152 J. C. Sadler, L. D. Humphreys, R. Snajdrova and G. A. Burley, *ChemBioChem*, 2017, **18**, 992–995.
- 153 C. Sommer-Kamann, A. Fries, S. Mordhorst, J. N. Andexer and M. Müller, *Angew. Chem., Int. Ed.*, 2017, **56**, 4033–4036.
- 154 S. Mordhorst and J. N. Andexer, *Nat. Prod. Rep.*, 2020, **37**, 1316–1333.
- 155 F. Michailidou and A. Rentmeister, *Org. Biomol. Chem.*, 2021, **19**, 3756–3762.
- 156 N. G. Schmidt, T. Pavkov-Keller, N. Richter, B. Wilschi, K. Gruber and W. Kroutil, *Angew. Chem., Int. Ed.*, 2017, **56**, 7615–7619.
- 157 A. Żądło-Dobrowolska, N. G. Schmidt and W. Kroutil, *ChemCatChem*, 2019, **11**, 1064–1068.
- 158 N. G. Schmidt and W. Kroutil, *Eur. J. Org. Chem.*, 2017, 5865–5871.
- 159 X. Sheng, M. Kazemi, A. Żądło-Dobrowolska, W. Kroutil and F. Himo, *ACS Catal.*, 2020, **10**, 570–577.
- 160 A. Żądło-Dobrowolska, L. Hammerer, T. Paykov-Keller, K. Gruber and W. Kroutil, *ACS Catal.*, 2020, **10**, 1094–1101.
- 161 P. S. Coelho, E. M. Brustad, A. Kannan and F. H. Arnold, *Science*, 2013, **339**, 307–310.
- 162 P. S. Coelho, Z. J. Wang, M. E. Ener, S. A. Baril, A. Kannan, F. H. Arnold and E. M. Brustad, *Nat. Chem. Biol.*, 2013, **9**, 485–U433.
- 163 N. S. Sarai, B. J. Levin, J. M. Roberts, D. E. Katsoulis and F. H. Arnold, *ACS Cent. Sci.*, 2021, **7**, 944–953.
- 164 A. Z. Zhou, K. Chen and F. H. Arnold, *ACS Catal.*, 2020, **10**, 5393–5398.
- 165 B. J. Wittmann, A. M. Knight, J. L. Hofstra, S. E. Reisman, S. B. J. Kan and F. H. Arnold, *ACS Catal.*, 2020, **10**, 7112–7116.
- 166 O. F. Brandenburg, K. Chen and F. H. Arnold, *J. Am. Chem. Soc.*, 2019, **141**, 8989–8995.
- 167 O. F. Brandenburg, R. Fasan and F. H. Arnold, *Curr. Opin. Biotechnol.*, 2017, **47**, 102–111.
- 168 Z. J. Wang, H. Renata, N. E. Peck, C. C. Farwell, P. S. Coelho and F. H. Arnold, *Angew. Chem., Int. Ed.*, 2014, **53**, 6810–6813.
- 169 J. E. Zhang, X. Y. Huang, R. J. K. Zhang and F. H. Arnold, *J. Am. Chem. Soc.*, 2019, **141**, 9798–9802.
- 170 K. Chen and F. H. Arnold, *J. Am. Chem. Soc.*, 2020, **142**, 6891–6895.
- 171 C. E. Paul, D. Eggerichs, A. H. Westphal, D. Tischler and W. J. H. van Berkel, *Biotechnol. Adv.*, 2021, **51**, 107712.
- 172 Y. H. Wang, D. M. Lan, R. Durrani and F. Hollmann, *Curr. Opin. Chem. Biol.*, 2017, **37**, 1–9.
- 173 V. B. Urlacher and M. Girhard, *Trends Biotechnol.*, 2019, **37**, 882–897.
- 174 M. K. Julsing, S. Cornelissen, B. Buhler and A. Schmid, *Curr. Opin. Chem. Biol.*, 2008, **12**, 177–186.
- 175 S. Chakrabarty, Y. Wang, J. C. Perkins and A. R. H. Narayan, *Chem. Soc. Rev.*, 2020, **49**, 8137–8155.
- 176 L. M. Blank, B. E. Ebert, K. Buehler and B. Buhler, *Antioxid. Redox Signaling*, 2010, **13**, 349–394.
- 177 W. A. Suske, W. J. H. van Berkel and H. P. E. Kohler, *J. Biol. Chem.*, 1999, **274**, 33355–33365.
- 178 W. A. Suske, M. Held, A. Schmid, T. Fleischmann, M. G. Wubolts and H. P. E. Kohler, *J. Biol. Chem.*, 1997, **272**, 24257–24265.
- 179 A. Meyer, A. Schmid, M. Held, A. H. Westphal, M. Rothlisberger, H. P. E. Kohler, W. J. H. van Berkel and B. Witholt, *J. Biol. Chem.*, 2002, **277**, 5575–5582.
- 180 A. Meyer, M. Wursten, A. Schmid, H. P. E. Kohler and B. Witholt, *J. Biol. Chem.*, 2002, **277**, 34161–34167.
- 181 A. Meyer, M. Held, A. Schmid, H. P. E. Kohler and B. Witholt, *Biotechnol. Bioeng.*, 2003, **81**, 518–524.
- 182 O. Shoji, T. Kunimatsu, N. Kawakami and Y. Watanabe, *Angew. Chem., Int. Ed.*, 2013, **52**, 6606–6610.
- 183 S. Ariyasu, J. K. Stanfield, Y. Aiba and O. Shoji, *Curr. Opin. Chem. Biol.*, 2020, **59**, 155–163.
- 184 H. Y. Zhou, B. J. Wang, F. Wang, X. J. Yu, L. X. Ma, A. T. Li and M. T. Reetz, *Angew. Chem., Int. Ed.*, 2019, **58**, 764–768.
- 185 S. D. Munday, S. Dezvarei, I. C. K. Lau and S. G. Bell, *ChemCatChem*, 2017, **9**, 2512–2522.
- 186 A. Dennig, A. M. Weingartner, T. Kardashliev, C. A. Muller, E. Tassano, M. Schurmann, A. J. Ruff and U. Schwaneberg, *Chem. – Eur. J.*, 2017, **23**, 17981–17991.



- 187 M. Karasawa, J. K. Stanfield, S. Yanagisawa, O. Shoji and Y. Watanabe, *Angew. Chem., Int. Ed.*, 2018, **57**, 12264–12269.
- 188 P. G. Gomez de Santos, M. Cañellas, F. Tieves, S. H. H. Younes, P. Molina-Espeja, M. Hofrichter, F. Hollmann, V. Guallar and M. Alcalde, *ACS Catal.*, 2018, **8**, 4789–4799.
- 189 E. Aranda, R. Ullrich and M. Hofrichter, *Biodegradation*, 2010, **21**, 267–281.
- 190 M. Kinne, R. Ullrich, K. E. Hammel, K. Scheibner and M. Hofrichter, *Tetrahedron Lett.*, 2008, **49**, 5950–5953.
- 191 R. Ullrich and M. Hofrichter, *Cell. Mol. Life Sci.*, 2007, **64**, 271–293.
- 192 P. Molina-Espeja, J. Viña-Gonzalez, B. J. Gomez-Fernandez, J. Martin-Diaz, E. Garcia-Ruiz and M. Alcalde, *Biotechnol. Adv.*, 2016, **34**, 754–767.
- 193 D. M. Mate, M. A. Palomino, P. Molina-Espeja, J. Martin-Diaz and M. Alcalde, *Protein Eng. Des. Sel.*, 2017, **30**, 191–198.
- 194 M. Petersen and A. Kiener, *Green Chem.*, 1999, **1**, 99–106.
- 195 A. Kiener, J. P. Roduit, A. Tschech, A. Tinschert and K. Heinzmann, *Synlett*, 1994, 814–816.
- 196 H. G. Kulla, *Chimia*, 1991, **45**, 81–85.
- 197 M. Nagel and J. R. Andreessen, *Arch. Microbiol.*, 1990, **154**, 605–613.
- 198 K. S. Ju and R. E. Parales, *Microbiol. Mol. Biol. Rev.*, 2010, **74**, 250–272.
- 199 M. R. Buddha, T. Tao, R. J. Parry and B. R. Crane, *J. Biol. Chem.*, 2004, **279**, 49567–49570.
- 200 S. C. Dodani, G. Kiss, J. K. B. Cahn, Y. Su, V. S. Pande and F. H. Arnold, *Nat. Chem.*, 2016, **8**, 419–425.
- 201 S. M. Barry, J. A. Kers, E. G. Johnson, L. J. Song, P. R. Aston, B. Patel, S. B. Krasnoff, B. R. Crane, D. M. Gibson, R. Loria and G. L. Challis, *Nat. Chem. Biol.*, 2012, **8**, 814–816.
- 202 S. Louka, S. M. Barry, D. J. Heyes, M. Q. E. Mubarak, H. S. Ali, L. M. Alkhalaf, A. W. Munro, N. S. Scrutton, G. L. Challis and S. P. de Visser, *J. Am. Chem. Soc.*, 2020, **142**, 15764–15779.
- 203 D. R. Boyd and T. D. H. Bugg, *Org. Biomol. Chem.*, 2006, **4**, 181–192.
- 204 D. R. Boyd, N. D. Sharma and C. C. R. Allen, *Curr. Opin. Biotechnol.*, 2001, **12**, 564–573.
- 205 T. Hudlicky, D. Gonzalez and D. T. Gibson, *Aldrichim. Acta*, 1999, **32**, 35–62.
- 206 T. Hudlicky and J. W. Reed, *Chem. Soc. Rev.*, 2009, **38**, 3117–3132.
- 207 B. D. Ensley and D. T. Gibson, *J. Bacteriol.*, 1983, **155**, 505–511.
- 208 S. V. Ley and F. Sternfeld, *Tetrahedron*, 1989, **45**, 3463–3476.
- 209 T. Hudlicky, H. Luna, G. Barbieri and L. D. Kwart, *J. Am. Chem. Soc.*, 1988, **110**, 4735–4741.
- 210 M. G. Banwell, A. J. Edwards, D. W. Lupton and G. Whited, *Aust. J. Chem.*, 2005, **58**, 14–17.
- 211 O. J. Kokas, M. G. Banwell and A. C. Willis, *Tetrahedron*, 2008, **64**, 6444–6451.
- 212 G. Guroff, J. W. Daly, D. M. Jerina, J. Renison, B. Witkop and S. Udenfriend, *Science*, 1967, **157**, 1524–1530.
- 213 W. Y. Zhang, H. H. Li, S. H. H. Younes, P. G. de Santos, F. Tieves, G. Grogan, M. Pabst, M. Alcalde, A. C. Whitwood and F. Hollmann, *ACS Catal.*, 2021, **11**, 2644–2649.
- 214 S. A. Baker Dockrey, A. L. Lukowski, M. R. Becker and A. R. H. Narayan, *Nat. Chem.*, 2018, **10**, 119–125.
- 215 M. Girhard, S. Schuster, M. Dietrich, P. Durre and V. B. Urlacher, *Biochem. Biophys. Res. Commun.*, 2007, **362**, 114–119.
- 216 I. Matsunaga, A. Ueda, N. Fujiwara, T. Sumimoto and K. Ichihara, *Lipids*, 1999, **34**, 841–846.
- 217 I. Funk, N. Rimmel, C. Schorsch, V. Sieber and J. Schmid, *J. Ind. Microbiol. Biotechnol.*, 2017, **44**, 1491–1502.
- 218 P. Durairaj, S. Malla, S. P. Nadarajan, P. G. Lee, E. Jung, H. H. Park, B. G. Kim and H. Yun, *Microb. Cell Factories*, 2015, **14**, 45.
- 219 P. Meinhold, M. W. Peters, A. Hartwick, A. R. Hernandez and F. H. Arnold, *Adv. Synth. Catal.*, 2006, **348**, 763–772.
- 220 C. Sathesh-Prabu and S. K. Lee, *J. Agric. Food Chem.*, 2015, **63**, 8199–8208.
- 221 M. J. Maseme, A. Pennec, J. van Marwijk, D. J. Opperman and M. S. Smit, *Angew. Chem., Int. Ed.*, 2020, **59**, 10359–10362.
- 222 J. Manning, M. Tavanti, J. L. Porter, N. Kress, S. P. De Visser, N. J. Turner and S. L. Flitsch, *Angew. Chem., Int. Ed.*, 2019, **58**, 5668–5671.
- 223 W. Lu, J. H. Feng, X. Chen, Y. J. Bao, Y. Wang, Q. Q. Wu, Y. H. Ma and D. M. Zhu, *Appl. Environ. Microbiol.*, 2019, **85**, e01182–01119.
- 224 W. Lu, X. Chen, J. H. Feng, Y. J. Bao, Y. Wang, Q. Q. Wu and D. M. Zhu, *Appl. Environ. Microbiol.*, 2018, **84**, e00503–00518.
- 225 Y. X. Li, B. Qin, X. Q. Li, J. Tang, Y. Chen, L. N. Zhou and S. You, *ChemCatChem*, 2018, **10**, 559–565.
- 226 K. D. Zhang, B. M. Shafer, M. D. Demars, H. A. Stern and R. Fasan, *J. Am. Chem. Soc.*, 2012, **134**, 18695–18704.
- 227 J. H. Z. Lee, S. H. Wong, J. E. Stok, S. A. Bagster, J. Beckett, J. K. Clegg, A. J. Brock, J. J. De Voss and S. G. Bell, *Arch. Biochem. Biophys.*, 2019, **663**, 54–63.
- 228 M. Tavanti, J. Mangas-Sanchez, S. L. Montgomery, M. P. Thompson and N. J. Turner, *Org. Biomol. Chem.*, 2017, **15**, 9790–9793.
- 229 H. Wang, Y. C. Zheng, F. F. Chen, J. H. Xu and H. L. Yu, *ChemCatChem*, 2020, **12**, 2077–2082.
- 230 Z. J. Jia, S. L. Gao and F. H. Arnold, *J. Am. Chem. Soc.*, 2020, **142**, 10279–10283.
- 231 C. K. Prier, R. J. K. Zhang, A. R. Buller, S. Brinkmann-Chen and F. H. Arnold, *Nat. Chem.*, 2017, **9**, 629–634.
- 232 J. Latham, E. Brandenburger, S. A. Shepherd, B. R. K. Menon and J. Micklefield, *Chem. Rev.*, 2018, **118**, 232–269.
- 233 J. Büchler, A. Papadopoulou and R. Buller, *Catalysts*, 2019, **9**, 1030.
- 234 D. S. Gkotsi, J. Dhaliwal, M. M. W. McLachlan, K. R. Mulholland and R. J. M. Goss, *Curr. Opin. Chem. Biol.*, 2018, **43**, 119–126.
- 235 M. Frese, P. H. Guzowska, H. Voss and N. Sewald, *ChemCatChem*, 2014, **6**, 1270–1276.



- 236 J. T. Payne, M. C. Andorfer and J. C. Lewis, *Angew. Chem., Int. Ed.*, 2013, **52**, 5271–5274.
- 237 J. Zeng and J. X. Zhan, *Biotechnol. Lett.*, 2011, **33**, 1607–1613.
- 238 S. A. Shepherd, C. Karthikeyan, J. Latham, A. W. Struck, M. L. Thompson, B. R. K. Menon, M. Q. Styles, C. Levy, D. Leys and J. Micklefield, *Chem. Sci.*, 2015, **6**, 3454–3460.
- 239 A. Phintha, K. Prakinee and P. Chaiyen, in *The Enzymes*, ed. P. Chaiyen and F. Tamanoi, Academic Press, 2020, vol. 47, ch. 11, pp. 327–364.
- 240 S. Unversucht, F. Hollmann, A. Schmid and K.-H. van Pée, *Adv. Synth. Catal.*, 2005, **347**, 1163–1167.
- 241 C. J. Dong, S. Flecks, S. Unversucht, C. Haupt, K.-H. van Pée and J. H. Naismith, *Science*, 2005, **309**, 2216–2219.
- 242 M. Ismail, L. Schroeder, M. Frese, T. Kottke, F. Hollmann, C. E. Paul and N. Sewald, *ACS Catal.*, 2019, **9**, 1389–1395.
- 243 L. Schroeder, M. Frese, C. Müller, N. Sewald and T. Kottke, *ChemCatChem*, 2018, **10**, 3336–3341.
- 244 C. Schnepel, V. I. Doderio and N. Sewald, *Chem. – Eur. J.*, 2021, **27**, 5404–5411.
- 245 C. Schnepel, H. Minges, M. Frese and N. Sewald, *Angew. Chem., Int. Ed.*, 2016, **55**, 14159–14163.
- 246 S. Dachwitz, D. H. Duwe, Y. H. Wang, H. Gruss, Y. Hannappel, T. Hellweg and N. Sewald, *Chem. – Eur. J.*, 2020, **26**, 16357–16364.
- 247 G. T. Höfler, A. But and F. Hollmann, *Org. Biomol. Chem.*, 2019, **17**, 9267–9274.
- 248 R. Wever, R. Renirie and F. Hollmann, *Vanadium Catalysis*, The Royal Society of Chemistry, 2021, pp. 548–563.
- 249 R. Wever, B. E. Krenn and R. Renirie, in *Methods Enzymol.*, ed. B. S. Moore, Academic Press, 2018, vol. 605, pp. 141–201.
- 250 E. Fernández-Fueyo, M. van Wingerden, R. Renirie, R. Wever, Y. Ni, D. Holtmann and F. Hollmann, *ChemCatChem*, 2015, **7**, 4035–4038.
- 251 V. Weichold, D. Milbredt and K. H. van Pee, *Angew. Chem., Int. Ed.*, 2016, **55**, 6374–6389.
- 252 D. Wischang and J. Hartung, *Tetrahedron*, 2011, **67**, 4048–4054.
- 253 D. Wischang, J. Hartung, T. Hahn, R. Ulber, T. Stumpf and C. Fecher-Trost, *Green Chem*, 2011, **13**, 102–108.
- 254 D. Thiel, F. Blume, C. Jaeger and J. Deska, *Eur. J. Org. Chem.*, 2018, 2717–2725.
- 255 D. Thiel, D. Doknic and J. Deska, *Nat. Commun.*, 2014, **5**, 5278.
- 256 E. Fernández-Fueyo, S. H. H. Younes, S. van Rootselaar, R. W. M. Aben, R. Renirie, R. Wever, D. Holtmann, F. P. J. T. Rutjes and F. Hollmann, *ACS Catal.*, 2016, **6**, 5904–5907.
- 257 S. H. H. Younes, F. Tieves, D. M. Lan, Y. H. Wang, P. Süß, H. Brundiek, R. Wever and F. Hollmann, *ChemSusChem*, 2020, **13**, 97–101.
- 258 G. T. Höfler, A. But, S. H. H. Younes, R. Wever, C. E. Paul, I. W. C. E. Arends and F. Hollmann, *ACS Sustainable Chem. Eng.*, 2020, **8**, 2602–2607.
- 259 J. Naapuri, J. D. Rolfes, J. Keil, C. M. Sapu and J. Deska, *Green Chem.*, 2017, **19**, 447–452.
- 260 X. M. Xu, A. But, R. Wever and F. Hollmann, *ChemCatChem*, 2020, **12**, 2180–2183.
- 261 A. But, E. van der Wijst, J. Le Nôtre, R. Wever, J. P. M. Sanders, J. H. Bitter and E. L. Scott, *Green Chem.*, 2017, **19**, 5178–5186.
- 262 A. But, J. Le Nôtre, E. L. Scott, R. Wever and J. P. M. Sanders, *ChemSusChem*, 2012, **5**, 1199–1202.
- 263 G. Y. Li, M. Garcia-Borràs, M. J. L. J. Fürst, A. Ilie, M. W. Fraaije, K. N. Houk and M. T. Reetz, *J. Am. Chem. Soc.*, 2018, **140**, 10464–10472.
- 264 Z. G. Zhang, G. D. Roiban, J. P. Acevedo, I. Polyak and M. T. Reetz, *Adv. Synth. Catal.*, 2013, **355**, 99–106.
- 265 J. Rehdorf, M. D. Mihovilovic and U. T. Bornscheuer, *Angew. Chem., Int. Ed.*, 2010, **49**, 4506–4508.
- 266 G. de Gonzalo, M. D. Mihovilovic and M. W. Fraaije, *ChemBioChem*, 2010, **11**, 2208–2231.
- 267 S. Schmidt, C. Scherkus, J. Muschiol, U. Menyes, T. Winkler, W. Hummel, H. Gröger, A. Liese, H. G. Herz and U. T. Bornscheuer, *Angew. Chem., Int. Ed.*, 2015, **54**, 2784–2787.
- 268 R. Karande, D. Salamanca, A. Schmid and K. Buehler, *Biotechnol. Bioeng.*, 2018, **115**, 312–320.
- 269 F. Hollmann, S. Kara, D. J. Opperman and Y. H. Wang, *Chem. – Asian J.*, 2018, **13**, 3601–3610.
- 270 A. Pennec, F. Hollmann, M. S. Smit and D. J. Opperman, *ChemCatChem*, 2015, **7**, 236–239.
- 271 K. Chen, S. Q. Zhang, O. F. Brandenburg, X. Hong and F. H. Arnold, *J. Am. Chem. Soc.*, 2018, **140**, 16402–16407.
- 272 S. B. J. Kan, X. Y. Huang, Y. Gumulya, K. Chen and F. H. Arnold, *Nature*, 2017, **552**, 132–136.
- 273 S. B. J. Kan, R. D. Lewis, K. Chen and F. H. Arnold, *Science*, 2016, **354**, 1048–1051.
- 274 Z. Wu, S. B. J. Kan, R. D. Lewis, B. J. Wittmann and F. H. Arnold, *Proc. Natl. Acad. Sci. U. S. A.*, 2019, **116**, 8852–8858.
- 275 S. Bahr, S. Brinkmann-Chen, M. Garcia-Borràs, J. M. Roberts, D. E. Katsoulis, K. N. Houk and F. H. Arnold, *Angew. Chem., Int. Ed.*, 2020, **59**, 15507–15511.
- 276 C. C. Farwell, J. A. McIntosh, T. K. Hyster, Z. J. Wang and F. H. Arnold, *J. Am. Chem. Soc.*, 2014, **136**, 8766–8771.
- 277 C. Patinios, L. Lanza, I. Corino, M. C. R. Franssen, J. van der Oost, R. A. Weusthuis and S. W. M. Kengen, *Front. Microbiol.*, 2020, **11**, 579844.
- 278 P. Bracco, N. van Midden, E. Arango, G. Torrelo, V. Ferrario, L. Gardossi and U. Hanefeld, *Catalysts*, 2020, **10**, 308.
- 279 A. H. J. Deniau, M. Subileau and E. Dubreucq, *ChemBioChem*, 2018, **19**, 1839–1844.
- 280 M. Subileau, A. H. Jan, J. Drone, C. Rutyna, V. Perrier and E. Dubreucq, *Catal. Sci. Technol.*, 2017, **7**, 2566–2578.
- 281 T. N. Nguyen, E. Dubreucq, V. Perrier, Q. H. Tran, C. Charpentier, C. Charnay, F. Terki, C. Jay-Allemand and L. P. R. Bidet, *Food Chem.*, 2020, **318**, 126482.
- 282 I. Mathews, M. Soltis, M. Saldajeno, G. Ganshaw, R. Sala, W. Weyler, M. A. Cervin, G. Whited and R. Bott, *Biochemistry*, 2007, **46**, 8969–8979.



- 283 C. Z. Dinu, I. V. Borkar, S. S. Bale, A. S. Campbell, R. S. Kane and J. S. Dordick, *J. Mol. Catal. B: Enzym.*, 2012, **75**, 20–26.
- 284 A. Drozd, U. Hanefeld, K. Szymanska, A. Jarzebski and A. Chrobok, *Catal. Commun.*, 2016, **81**, 37–40.
- 285 N. de Leeuw, G. Torrelo, C. Bisterfeld, V. Resch, L. Mestrom, E. Straulino, L. van der Weel and U. Hanefeld, *Adv. Synth. Catal.*, 2018, **360**, 242–249.
- 286 E. Jost, M. Kazemi, V. Mrkonjic, F. Himo, C. K. Winkler and W. Kroutil, *ACS Catal.*, 2020, **10**, 10500–10507.
- 287 S. P. Godehard, C. P. S. Badenhorst, H. Müller and U. T. Bornscheuer, *ACS Catal.*, 2020, **10**, 7552–7562.
- 288 L. Mestrom, J. G. R. Claessen and U. Hanefeld, *ChemCatChem*, 2019, **11**, 2004–2010.
- 289 H. Land, P. Hendil-Forsell, M. Martinelle and P. Berglund, *Catal. Sci. Technol.*, 2016, **6**, 2897–2900.
- 290 M. L. Contente, A. Pinto, F. Molinari and F. Paradisi, *Adv. Synth. Catal.*, 2018, **360**, 4814–4819.
- 291 M. L. Contente, L. Tamborini, F. Molinari and F. Paradisi, *J. Flow Chem.*, 2020, **10**, 235–240.
- 292 K. Szymanska, K. Odrozek, A. Zniszczol, G. Torrelo, V. Resch, U. Hanefeld and A. B. Jarzebski, *Catal. Sci. Technol.*, 2016, **6**, 4882–4888.
- 293 M. Finnveden, S. Semlitsch, O. He and M. Martinelle, *Catal. Sci. Technol.*, 2019, **9**, 4920–4927.
- 294 H. Müller, S. P. Godehard, G. J. Palm, L. Berndt, C. P. S. Badenhorst, A. K. Becker, M. Lammers and U. T. Bornscheuer, *Angew. Chem., Int. Ed.*, 2021, **60**, 2013–2017.
- 295 Z. Z. Yan, L. P. Ding, D. D. Zou, L. Y. Wang, Y. Z. Tan, S. T. Guo, Y. C. Zhang and Z. H. Xin, *Arch. Microbiol.*, 2021, **203**, 4113–4125.
- 296 H. Müller, A. K. Becker, G. J. Palm, L. Berndt, C. P. S. Badenhorst, S. P. Godehard, L. Reisky, M. Lammers and U. T. Bornscheuer, *Angew. Chem., Int. Ed.*, 2020, **59**, 11607–11612.
- 297 P. Pongpamorn, C. Kiattisewee, N. Kittipanukul, J. Jaroensuk, D. Trisrivirat, S. Maenpuen and P. Chaiyen, *Angew. Chem., Int. Ed.*, 2021, **60**, 5749–5753.
- 298 M. L. Contente, S. Farris, L. Tamborini, F. Molinari and F. Paradisi, *Green Chem.*, 2019, **21**, 3263–3266.
- 299 I. C. Perdomo, S. Gianolio, A. Pinto, D. Romano, M. L. Contente, F. Paradisi and F. Molinari, *J. Agric. Food Chem.*, 2019, **67**, 6517–6522.
- 300 F. Annunziata, M. L. Contente, D. Betti, C. Pinna, F. Molinari, L. Tamborini and A. Pinto, *Catalysts*, 2020, **10**, 939.
- 301 M. L. Contente, D. R. Padrosa, F. Molinari and F. Paradisi, *Nat. Catal.*, 2020, **3**, 1020–1026.
- 302 A. J. L. Wood, N. J. Weise, J. D. Frampton, M. S. Dunstan, M. A. Hollas, S. R. Derrington, R. C. Lloyd, D. Quaglia, F. Parmeggiani, D. Leys, N. J. Turner and S. L. Flitsch, *Angew. Chem., Int. Ed.*, 2017, **56**, 14498–14501.
- 303 A. N. Johnson, D. E. Barlow, A. L. Kelly, V. A. Varaljay, W. J. Crookes-Goodson and J. C. Biffinger, *Polym. Int.*, 2021, **70**, 977–983.
- 304 S. Yoshida, K. Hiraga, T. Takehana, I. Taniguchi, H. Yamaji, Y. Maeda, K. Toyohara, K. Miyamoto, Y. Kimura and K. Oda, *Science*, 2016, **351**, 1196–1199.
- 305 M. O'Reilly and J. Stubbe, *Biochemistry*, 2020, **59**, 2316–2318.
- 306 V. Tournier, C. M. Topham, A. Gilles, B. David, C. Folgoas, E. Moya-Leclair, E. Kamionka, M. L. Desrousseaux, H. Texier, S. Gavalda, M. Cot, E. Guemard, M. Dalibey, J. Nomme, G. Cioci, S. Barbe, M. Chateau, I. Andre, S. Duquesne and A. Marty, *Nature*, 2020, **580**, 216–219.
- 307 H. Sawai, H. Sugimoto, Y. Kato, Y. Asano, Y. Shiro and S. Aono, *J. Biol. Chem.*, 2009, **284**, 32089–32096.
- 308 A. Hinzmann, T. Betke, Y. Asano and H. Gröger, *Chem. – Eur. J.*, 2021, **27**, 5313–5321.
- 309 A. Hinzmann, M. Stricker and H. Gröger, *ACS Sustainable Chem. Eng.*, 2020, **8**, 17088–17096.
- 310 H. Gröger and Y. Asano, *J. Org. Chem.*, 2020, **85**, 6243–6251.
- 311 D. Ribeaucourt, B. Bissaro, V. Guallar, M. Yemloul, M. Haon, S. Grisel, V. Alphand, H. Brumer, F. Lambert, J. G. Berrin and M. Lafond, *ACS Sustainable Chem. Eng.*, 2021, **9**, 4411–4421.
- 312 D. Ribeaucourt, B. Bissaro, F. Lambert, M. Lafond and J.-G. Berrin, *Biotechnol. Adv.*, 2021, 107787.
- 313 P. Le-Huu, T. Heidt, B. Claasen, S. Laschat and V. B. Urlacher, *ACS Catal.*, 2015, **5**, 1772–1780.
- 314 H. Xiao, S. Dong, Y. Liu, X. Q. Pei, H. Lin and Z. L. Wu, *Catal. Sci. Technol.*, 2021, **11**, 2195–2201.
- 315 M. K. Julsing, D. Kuhn, A. Schmid and B. Buhler, *Biotechnol. Bioeng.*, 2012, **109**, 1109–1119.
- 316 D. Kuhn, M. A. Kholiq, E. Heinzle, B. Buhler and A. Schmid, *Green Chem.*, 2010, **12**, 815–827.
- 317 Y. Zhang, Y. Q. Wu, N. Xu, Q. Zhao, H. L. Yu and J. H. Xu, *ACS Sustainable Chem. Eng.*, 2019, **7**, 7218–7226.
- 318 T. Heine, A. Scholtissek, S. Hofmann, R. Koch and D. Tischler, *ChemCatChem*, 2020, **12**, 199–209.
- 319 D. Tischler, A. Kumpf, D. Eggerichs and T. Heine, in *The Enzymes*, ed. P. Chaiyen and F. Tamanoi, Academic Press, 2020, vol. 47, ch. 13, pp. 399–425.
- 320 B. V. Plapp, B. R. Savarimuthu, D. J. Ferraro, J. K. Rubach, E. N. Brown and S. Ramaswamy, *Biochemistry*, 2017, **56**, 3632–3646.
- 321 B. V. Plapp, *Arch. Biochem. Biophys.*, 2010, **493**, 3–12.
- 322 J. H. An, Y. Nie and Y. Xu, *Crit. Rev. Biotechnol.*, 2019, **39**, 366–379.
- 323 A. Weckbecker and W. Hummel, *Biocatal. Biotransform.*, 2006, **24**, 380–389.
- 324 S. Kara, J. H. Schrittwieser, F. Hollmann and M. B. Ansorge-Schumacher, *Appl. Microbiol. Biotechnol.*, 2014, **98**, 1517–1529.
- 325 T. S. Moody and J. D. Rozzell, in *Organic Synthesis Using Biocatalysis*, ed. A. Goswami and J. D. Stewart, Academic Press, 2016, pp. 149–185.
- 326 W. Jiang and B. S. Fang, *Appl. Biochem. Biotechnol.*, 2020, **192**, 146–179.
- 327 S. K. Ma, J. Gruber, C. Davis, L. Newman, D. Gray, A. Wang, J. Grate, G. W. Huisman and R. A. Sheldon, *Green Chem.*, 2010, **12**, 81–86.
- 328 D. Pollard, M. Truppo, J. Pollard, C. Y. Chen and J. Moore, *Tetrahedron: Asymmetry*, 2006, **17**, 554–559.
- 329 J. Liang, E. Mundorff, R. Voladri, S. Jenne, L. Gilson, A. Conway, A. Krebber, J. Wong, G. Huisman, S. Truesdell and J. Lalonde, *Org. Process Res. Dev.*, 2010, **14**, 188–192.





- 330 C. V. Voss, C. C. Gruber and W. Kroutil, *Synlett*, 2010, 991–998.
- 331 C. E. Paul, I. Lavandera, V. Gotor-Fernández, W. Kroutil and V. Gotor, *ChemCatChem*, 2013, **5**, 3875–3881.
- 332 O. W. Gooding, R. Voladri, A. Bautista, T. Hopkins, G. Huisman, S. Jenne, S. Ma, E. C. Mundorff and M. M. Savile, *Org. Process Res. Dev.*, 2010, **14**, 119–126.
- 333 J. A. Friest, Y. Maezato, S. Broussy, P. Blum and D. B. Berkowitz, *J. Am. Chem. Soc.*, 2010, **132**, 5930–5931.
- 334 M. Hohne, *Nat. Catal.*, 2019, **2**, 841–842.
- 335 S. C. Cosgrove, A. Brzezniak, S. P. France, J. I. Ramsden, J. Mangas-Sanchez, S. L. Montgomery, R. S. Heath and N. J. Turner, *Enzymes Synth. Biol.*, 2018, **608**, 131–149.
- 336 J. Mangas-Sánchez, S. P. France, S. L. Montgomery, G. A. Aleku, H. Man, M. Sharma, J. I. Ramsden, G. Grogan and N. J. Turner, *Curr. Opin. Chem. Biol.*, 2017, **37**, 19–25.
- 337 O. Mayol, K. Bastard, L. Beloti, A. Frese, J. P. Turkenburg, J. L. Petit, A. Mariage, A. Debard, V. Pellouin, A. Perret, V. de Berardinis, A. Zaparucha, G. Grogan and C. Vergne-Vaxelaire, *Nat. Catal.*, 2019, **2**, 324–333.
- 338 O. Mayol, S. David, E. Darii, A. Debard, A. Mariage, V. Pellouin, J. L. Petit, M. Salanoubat, V. de Berardinis, A. Zaparucha and C. Vergne-Vaxelaire, *Catal. Sci. Technol.*, 2016, **6**, 7421–7428.
- 339 T. Knaus, W. Bohmer and F. G. Mutti, *Green Chem.*, 2017, **19**, 453–463.
- 340 A. S. Bommarius, *Nat. Catal.*, 2019, **2**, 288–289.
- 341 M. J. Abrahamson, E. Vazquez-Figueroa, N. B. Woodall, J. C. Moore and A. S. Bommarius, *Angew. Chem., Int. Ed.*, 2012, **51**, 3969–3972.
- 342 G. A. Aleku, S. P. France, H. Man, J. Mangas-Sanchez, S. L. Montgomery, M. Sharma, F. Leipold, S. Hussain, G. Grogan and N. J. Turner, *Nat. Chem.*, 2017, **9**, 961–969.
- 343 M. Sharma, J. Mangas-Sanchez, S. P. France, G. A. Aleku, S. L. Montgomery, J. I. Ramsden, N. J. Turner and G. Grogan, *ACS Catal.*, 2018, **8**, 11534–11541.
- 344 L. Ducrot, M. Bennett, G. Grogan and C. Vergne-Vaxelaire, *Adv. Synth. Catal.*, 2021, **363**, 328–351.
- 345 S. P. France, R. M. Howard, J. Stefflik, N. J. Weise, J. Mangas-Sanchez, S. L. Montgomery, R. Crook, R. Kumar and N. J. Turner, *ChemCatChem*, 2018, **10**, 510–514.
- 346 G. H. Kim, H. Jeon, T. P. Khobragade, M. D. Patil, S. Sung, S. Yoon, Y. Won, I. S. Choi and H. Yun, *Enzyme Microb. Technol.*, 2019, **120**, 52–60.
- 347 C. K. Savile, J. M. Janey, E. C. Mundorff, J. C. Moore, S. Tam, W. R. Jarvis, J. C. Colbeck, A. Krebber, F. J. Fleitz, J. Brands, P. N. Devine, G. W. Huisman and G. J. Hughes, *Science*, 2010, **329**, 305–309.
- 348 S. L. Montgomery, A. Pushpanath, R. S. Heath, J. R. Marshall, U. Klemstein, J. L. Galman, D. Woodlock, S. Bisagni, C. J. Taylor, J. Mangas-Sanchez, J. I. Ramsden, B. Dominguez and N. J. Turner, *Sci. Adv.*, 2020, **6**, eaay9320.
- 349 J. Mangas-Sanchez, M. Sharma, S. C. Cosgrove, J. I. Ramsden, J. R. Marshall, T. W. Thorpe, R. B. Palmer, G. Grogan and N. J. Turner, *Chem. Sci.*, 2020, **11**, 5052–5057.
- 350 V. F. Batista, J. L. Galman, D. C. G. A. Pinto, A. M. S. Silva and N. J. Turner, *ACS Catal.*, 2018, **8**, 11889–11907.
- 351 S. R. Derrington, N. J. Turner and S. P. France, *J. Biotechnol.*, 2019, **304**, 78–88.
- 352 M. Winkler, *Curr. Opin. Chem. Biol.*, 2018, **43**, 23–29.
- 353 M. Lubberink, C. Schnepel, J. Citoler, S. R. Derrington, W. Finnigan, M. A. Hayes, N. J. Turner and S. L. Flitsch, *ACS Catal.*, 2020, **10**, 10005–10009.
- 354 C. K. Winkler, K. Faber and M. Hall, *Curr. Opin. Chem. Biol.*, 2018, **43**, 97–105.
- 355 H. S. Toogood and N. S. Scrutton, *ACS Catal.*, 2018, **8**, 3532–3549.
- 356 T. Ress, W. Hummel, S. P. Hanlon, H. Iding and H. Gröger, *ChemCatChem*, 2015, **7**, 1302–1311.
- 357 A. Scholtissek, D. Tischler, A. H. Westphal, W. J. H. van Berkel and C. E. Paul, *Catalysts*, 2017, **7**, 130.
- 358 T. Knaus, C. E. Paul, C. W. Levy, S. de Vries, F. G. Mutti, F. Hollmann and N. S. Scrutton, *J. Am. Chem. Soc.*, 2016, **138**, 1033–1039.
- 359 H. S. Toogood, T. Knaus and N. S. Scrutton, *ChemCatChem*, 2014, **6**, 951–954.
- 360 A. Muller, R. Sturmer, B. Hauer and B. Rosche, *Angew. Chem., Int. Ed.*, 2007, **46**, 3316–3318.
- 361 B. A. Sandoval and T. K. Hyster, *Curr. Opin. Chem. Biol.*, 2020, **55**, 45–51.
- 362 X. Huang, B. Wang, Y. Wang, G. Jiang, J. Feng and H. Zhao, *Nature*, 2020, **584**, 69–74.
- 363 C. A. Roessner, J. B. Spencer, N. J. Stolowich, J. Wang, G. Parmesh Nayar, P. J. Santander, C. Pichon, C. Min, M. T. Holderman and A. I. Scott, *Chem. Biol.*, 1994, **1**, 119–124.
- 364 A. I. Scott, *Synlett*, 1994, 871–883.
- 365 N. Losada-Garcia, Z. Cabrera, P. Urrutia, C. Garcia-Sanz, A. Andreu and J. M. Palomo, *Catalysts*, 2020, **10**, 1258.
- 366 M. P. Thompson, I. Penafiel, S. C. Cosgrove and N. J. Turner, *Org. Process Res. Dev.*, 2019, **23**, 9–18.
- 367 M. Santi, L. Sancineto, V. Nascimento, J. B. Azeredo, E. V. M. Orozco, L. H. Andrade, H. Gröger and C. Santi, *Int. J. Mol. Sci.*, 2021, **22**, 990.
- 368 J. M. Woodley, *Green Biocatalysis*, 2016, pp. 503–518.
- 369 S. M. K. McKinnie, Z. D. Miles, P. A. Jordan, T. Awakawa, H. P. Pepper, L. A. M. Murray, J. H. George and B. S. Moore, *J. Am. Chem. Soc.*, 2018, **140**, 17840–17845.
- 370 Z. L. Wang, B. S. Sekar and Z. Li, *Bioresour. Technol.*, 2021, **323**, 124551.
- 371 J. H. Schrittwieser, S. Velikogne, M. Hall and W. Kroutil, *Chem. Rev.*, 2018, **118**, 270–348.

